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 The processing and integration of information in the brain depends on cel-to-cel 
communication. Synapses, the sites of communication, are specialized asymmetrical 
connections between neurons that alow for the eficient transfer of information. Synaptic 
formation, structure, maturation, and maintenance are sustained by a multifarious 
network of bidirectional celular adhesion molecules that span the synaptic cleft, aligning 
the presynaptic active zone and postsynaptic density. Arguably, the best-characterized 
synaptic cel adhesion molecules are the presynaptic neurexins and postsynaptic 
neuroligins. The transsynaptic heterophilic interaction between the extracelular domains 
of neuroligins and neurexins can induce synapse formation and maturation. Although 
intensely studied, the signaling pathways that regulate neuroligins ability to generate, 
maintain, and strengthen functional synapses in the developing and mature brain are 
largely unknown. 
 The genesis of new synapses by neuroligin has been shown to be dependent on 
Ca2+/CaM Kinase I, but the mechanism behind this regulation is unknown. Here, we 
report that Ca2+/CaM Kinase I robustly phosphorylates the intracelular domain of 
neuroligin-1 on T739 in response to sensory experience in the brain. Blocking 
phosphorylation drasticaly decreases neuroligin-1 surface expression, thereby reducing 
its ability to induce synaptogenesis. Therefore we report that neuroligin is indeed 
changed by ongoing activity and a direct link between synaptogenesis and calcium in the 
cel. 
 In humans, alterations that perturb neuroligins are implicated in cognitive 
disorders, highlighting their critical roles at the synapse. However, the mechanisms by 
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which the majority of these mutations may contribute to the disease are unknown. Here 
we show that endogenous neuroligin-4X is robustly phosphorylated by protein kinase C 
at T707. Furthermore, R704C, a wel-described autism mutation, completely eliminates 
T707 phosphorylation. A phospho-mimetic mutation at T707 has a profound efect on 
neuroligin-4X-mediated excitatory potentiation. Our results now establish an important 
interplay between a genetic mutation, a key postranslational modification, and robust 
synaptic changes, which can provide insights into the synaptic dysfunction of autism 
spectrum disorders. 
 The extracelular domain of neuroligin-3 promotes glioma growth. Neuroligin-3 
expression inversely corelates with survival in human glioblastoma providing a link 
between neuroligins and cancer. How neuroligin-3 is processed to produce solely its 
extracelular domain remains an enigma. Here, we report that protein kinase C signaling 
induces the proteolytic cleavage of ful-length neuroligin-3 to produce the extracelular 
domain. We show that this regulation is isoform and kinase specific. Therefore we report 
a functional interplay between protein kinase C signaling and neuroligin-3, which may 
play a role in the etiology of brain cancer. 
 Taken together, these studies described in this thesis contribute to and expand the 
understanding of the mechanisms governing synaptogenesis. Historicaly, neuroligins 
have been viewed as static building blocks of synapses. Our research identifies pathways 
by which neuroligins are transiently modified and acutely enhance synapses in an 
activity-dependent manner. The aberant regulation of neuroligins contributes to 
disorders ranging from autism spectrum disorders to cancer underlying their importance 
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Chapter 1 entitled An Overview of Neuroligin Subtype Conservation and Subcelular 







Conservation Among Subtypes 
 A fundamental physical interaction exists across the synapse. It is mediated by 
synaptic adhesion molecules, and is among the earliest and most indispensable of 
molecular events occuring during synaptogenesis. The regulation of adhesion molecules 
and their interactions with other synaptic proteins (receptors, scafolds, and linkers) likely 
impacts not only synapse formation, but also ongoing synaptic function (Figure 1-1). 
One major family of postsynaptic adhesion molecules is neuroligins, which bind to their 
presynaptic partner neurexin across the synaptic cleft.  
 Neuroligins are a class of adhesion molecules found at postsynaptic sites in 
neurons (Nguyen and Sudhof, 1997). The four major members of the class are 
neuroligins (NLGNs) 1, 2, 3, and 4, which each share gross structural similarity and 
substantial conservation in amino acid sequence (Figure 1-2A). Each neuroligin has a 
single transmembrane region separating an acetylcholinesterase-like domain in the 
extracelular space from a short cytoplasmic tail (Bemben et al., 2015b; Choi et al., 
2011a; Nguyen and Sudhof, 1997; Sudhof, 2008). The extracelular domains of NLGNs1-
3 contain two notable alternative splice sites that can afect the specificity of trans-
synaptic adhesive interactions with repercussions for celular function (Chih et al., 2006; 
Koehnke et al., 2010; Lee et al., 2010; Shipman and Nicol, 2012b). However, the 
extracelular domain is otherwise more conserved than the intracelular domain (Figure 
1-2B). There is an additional fifth gene in humans – NLGN4Y (occasionaly refered to 
as NLGN5) – found on the Y chromosome that is greater than 97% identical in protein 
sequence to NLGN4X, on the X chromosome (Figure 1-2C). Due to the high level of 
molecular similarity, we wil discuss NLGN4X and NLGN4Y together as NLGN4.  
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Neuroligins are situated within a larger superfamily of post-synaptic adhesion 
molecules, including, but not limited to: cadherins, SynCAMs, LRRTMs, GluD2, CL1, 
NGLs, and teneurins (Arikkath and Reichardt, 2008; Biederer et al., 2002; Boucard et al., 
2012; de Wit et al., 2009; Ko et al., 2009a; Linhof et al., 2009; Mosca et al., 2012; 
Uemura et al., 2010; Woo et al., 2009). On the presynaptic side, the primary adhesion 
partner of neuroligins is the neurexin family, which is itself composed of many subtypes 
and a vast number of splice variants (Treutlein et al., 2014; Ulrich et al., 1995). This 
diversity of synaptic adhesion molecules suggests the possibility that a trans-synaptic 
molecular code could participate in the formation or ongoing function of the diverse 






















Figure 1-1. Schematic Diagram of a Subset of Protein Constituents at Excitatory 
and Inhibitory Synapses. Neuroligins bind a diverse set of proteins at glutamatergic and 
GABAergic/glycinergic synapses. (protein abbreviations are: alpha-dystroglycan (α-DG); 
α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor (AMPAR); beta-
dystroglycan (β-DG); Ca2+/calmodulin-dependent protein kinase I (CaMKI); colybistin 
(CB); cortical actin binding protein (Cortactin); gamma-aminobutyric acida receptor 
(GABAaR); guanylate kinase-associated protein (GKAP); glycine receptor (GlyR); 
immunoglobin superfamily member 9b (IgSF9b); inositol trisphosphate 3 receptor 
(IP3R); kainate receptor (KAR); potassium channel (KCh); leucine-rich transmembrane 
protein 2 (LRRTM2); MAM domain-containing glycosylphosphatidylinositol anchor 1 






















































(NMDAR); profilin (PFN); postsynaptic density protein 95 (PSD-95); protein tyrosine 
phosphatase rho (PTPσ); synaptic scafolding molecule (S-SCAM); SH3 and ankyrin 
repeat-containing protein (Shank); Slit- and NTRK-like family (Slitrk); syntrophin 
(SNTA); spine-associated RapGAP (SPAR); TCR gamma alternate reading from protein 
(TARP); vasodilator-stimulated phosphoprotein (VASP); protein domain abbreviations 
are: Dbl homology domain (DH); enabled/VASP homology domain (EVH); guanylate 
kinase-like domain (GK); PSD-95/Discs large/ZO-1 (PDZ); pleckstrin homology domain 























Figure 1-2. Neuroligin Subtypes. A. Subtypes of neuroligin with shared identity. Plots 
behind each molecule show percent identity to a group containing NLGNs 1-4 (blasp, 
sliding average 10 amino acids). Dark bar in the identity plot indicates the 
transmembrane domain. B. Matrix depicting the approximate percentage identity of the 
diferent human neuroligin protein sequences, excluding extracelular splice sites, 
separated by domain (EXT: extracelular; INT: intracelular). C. Distance model of 
neuroligin subtypes (Jukes-Cantor Model). Scale is given as residue substitutions per site. 
D. Schematic of synaptic adhesion superfamily (abbreviations: leukocyte common 
antigen-related receptor protein tyrosine phosphatase (LAR PTPR); leucine-rich repeat 
transmembrane protein (LRRTM); cerebelin (Clbn); CIRL1/latrophilin-1 (CL1); netrin-










Al neuroligins have a conserved domain structure and are postsynaptic 
molecules. However, the diferent subtypes of neuroligin each display unique subcelular 
localizations. Classicaly, NLGN1 is localized to excitatory (glutamatergic) synapses; 
NLGN2 is localized to inhibitory (GABAergic) synapses; and NLGN3 is localized to 
both excitatory and inhibitory synapses (Figure 1-3A). This patern was initialy 
discovered via immunostaining and biochemical analysis (Budreck and Scheifele, 2007; 
Graf et al., 2004; Song et al., 1999; Varoqueaux et al., 2004), and has been subsequently 
supported by functional experiments (Chubykin et al., 2007; Shipman et al., 2011). The 
odd member of the family, NLGN4, unlike NLGNs1-3, is poorly conserved from humans 
to mice (~58%), despite strong conservation in other species such as chicken (>93%) and 
opossum (>95%) among others, and the mouse NLGN4-like gene is not even fuly 
conserved among strains (Boliger et al., 2008). Nonetheless, a NLGN4-like protein in 
mice has been shown to localize both to GABAergic synapses in the CNS as wel as 
glycinergic synapses in the retina (Hoon et al., 2011). 
Outside the nervous system, NLGN2 has been found on the surface of pancreatic 
β cels, where it stimulates the secretion of insulin through a trans-celular, clustering-
dependent, but neurexin-independent mechanism (Suckow et al., 2012). Perhaps further 
study of this related, but clearly unique, system could yield insight into the most 







The canonical interactions between neuroligin molecules folow a patern that 
aligns with their subcelular localization. The primary species of neuroligin in the cel is a 
dimer, if not a higher-order oligomer. The neuroligin dimer was initialy infered from 
similarity to the protein sequence of acetylcholinesterase (Comoleti et al., 2003), and the 
presence of a dimer has been supported both biochemicaly as wel as functionaly: 
mutations in the extracelular domain based on the acetylcholinesterase structure abolish 
both the biochemical dimer and the overexpression phenotype of the molecule (Dean et 
al., 2003). When the crystal structure of the neuroligin extracelular domain was later 
determined, it confirmed dimerization highly reminiscent of cholinesterases (Arac et al., 
2007; Comoleti et al., 2007; Fabrichny et al., 2007; Koehnke et al., 2008). With structure 
in hand, function was revisited: a series of mutations that abolish dimerization were 
found to induce a coresponding reduction in function (Ko et al., 2009b). There is some 
evidence that dimerization is a necessary step in the traficking of neuroligin 
(Poulopoulos et al., 2012), although this is not undisputed (Shipman and Nicol, 2012a). 
Finaly, using variants of neuroligin in which dimerization of neuroligin can be controled 
via a smal molecule, it was shown that dimerization is, indeed, necessary for neuroligin’s 
synaptogenic efect (Shipman and Nicol, 2012a). 
Most of the structural and functional work has focused on neuroligin 
homodimerization. However, biochemical studies have given us insight into the rules that 
govern inter-type, or heterodimerization. Using co-immunoprecipitation, NLGNs 1-3 
were each shown to homodimerize, but; whereas, NLGN3 was able to heterodimerize 
with both NLGN1 and NLGN2, there was no apparent dimerization between NLGN1 and 
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NLGN2 (Budreck and Scheiffele, 2007). The heterodimerization between NLGN1 and 
NLGN3 has been multiply confirmed (Poulopoulos et al., 2012; Shipman et al., 2011), 
whereas a separate investigation of endogenous neuroligin found traces of a NLGN1/2 
dimer and the absence of a NLGN2/3 dimer (Poulopoulos et al., 2012). Moreover, homo- 
or hetero-dimerization of NLGN4 is completely untested (Figure 1-3B). Rigorous 
determination of the most prevalent complexes as wel as whether there may be cel-type 
specific complexes is an area that deserves further experimentation.   
Finaly, it is not clear whether individual dimers of neuroligin or in fact higher-
order oligomers are the primary species present at a synaptic site (Figure 1-3C,D). There 
is evidence that a multimer of neuroligin must cluster at least four neurexin molecules to 
achieve synaptogenic efects (Dean et al., 2003). Moreover, the NLGN1/neurexin1β 
extracelular domains can form a higher-order latice sheet when crystalized, whereas the 
NLGN1/neurexin1α domains cannot (Tanaka et al., 2012). Although yet to be tested 
functionaly, perhaps this is another mechanism by which adhesion molecules may 













Figure 1-3. Localization and Dimerization. A. Localization of neuroligins: NLGN1 and 
NLGN3 at excitatory synapses; NLGN2 and NLGN3 at inhibitory synapses. Shown also 
in the synapse are an AMPA receptor (in light blue) and GABA receptor (in purple). B. 
Confirmed, disputed, and untested dimers of neuroligin subtypes. C. Model of a synapse 













































Chapter 2 entitled Neuroligin: Binding Partners and Post-Translational 






 After neuroligin isoforms were found to induce the genesis of distinct synaptic 
subtypes, researchers looked for the critical domains and protein interactions that are 
required. The first identified postsynaptic binding partner with the cytoplasmic tail (c-
tail) of neuroligins was postsynaptic density protein 95 (PSD-95), a canonical constituent 
of glutamatergic synapses (Irie et al., 1997). The PDZ ligand is conserved among al 
neuroligin isoforms (Figure 2-1) and interacts with the third PDZ domain within PSD-
95. In addition to PSD-95, neuroligins bind to other members of the membrane-
associated guanylate kinase (MAGUK) family (Meyer et al., 2004), although the 
functional significance of these interactions remains to be determined. Interestingly, 
NLGN1 successfuly trafics to the synapse (Dresbach et al., 2004) and NLGN3 is able to 
robustly potentiate synapses independent of their PDZ ligands (Shipman et al., 2011). 
Due to complete conservation throughout the family, it seems unlikely the PDZ ligand is 
the dominant factor that dictates the diferential localization of neuroligin subtypes. 
 Similar to PSD-95, Synaptic Scafolding Molecule (S-SCAM) was shown to bind 
to NLGN1 and NLGN2 via a yeast-two hybrid screen (Hirao et al., 1998; Meyer et al., 
2004). NLGN1 and NLGN2 bind to two diferent regions within S-SCAM: a PDZ- and a 
WW-domain (Iida et al., 2004; Sumita et al., 2007). Researchers only tested S-SCAM 
binding to NLGN1 and NLGN2, but both the PDZ ligand and WW-binding domain are 
conserved among al neuroligin subtypes (Figure 2-1). Therefore, it is conceivable that 
al neuroligins bind to S-SCAM, similar to PSD-95 and, indeed, S-SCAM is present at 
both excitatory and inhibitory synapses. To rigorously test the importance of this 
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interaction, both the PDZ- and WW-interacting sites would need to be simultaneously 
mutated in NLGN1 or NLGN2.  
 At GABAergic synapses, NLGN2 was shown to co-localize with and recruit 
gephyrin (an inhibitory scafolding molecule) to nascent postsynaptic specializations 
(Graf et al., 2004; Varoqueaux et al., 2004) and an unbiased screen further identified 
gephyrin as a direct NLGN2 interactor. However, like PSD-95 and S-SCAM, the 
gephyrin-binding domain in NLGN2 is conserved and binds equaly wel to NLGN1, 
NLGN2, and NLGN3 (Poulopoulos et al., 2009) (Figure 2-1). Therefore NLGN2’s 
specificity to inhibitory synapses cannot solely be atributed to the gephyrin-binding 
sequence. Recent studies suggest phosphorylation of NLGN1 and NLGN2 may, at least 
in part, dictate the afinity of gephyrin to a particular neuroligin isoform (Giannone et al., 
2013) (discussed further below), providing a possible explanation for synapse specificity.  
 Research into colybistin may provide another clue to the localization and 
function of NLGN2. Colybistin is a key inhibitory synapse molecule that binds gephyrin 
and recruits it to the plasma membrane, where gephyrin can self-assemble and cluster 
critical inhibitory receptors, a prevailing model for inhibitory postsynaptic diferentiation 
(Harvey et al., 2004; Kins et al., 2000). Remarkably, only inhibitory neuroligins (NLGN2 
and mouse NLGN4) bind to colybistin’s SH3 domain, promote an open/active 
confirmation, and trafic gephyrin and colybistin to plasma membrane phosphoinositides 
(Hoon et al., 2011; Poulopoulos et al., 2009; Soykan et al., 2014). The colybistin-binding 
domain is unknown but has been predicted to involve the poly-proline region near the 
terminal end of the NLGN2 c-tail (Figure 2-1). This region is not conserved in NLGN1, 
NLGN3 (Papadopoulos and Soykan, 2011), or NLGN4 (mouse), suggestive of an 
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independent binding site in NLGN4. A direct test of this two-step, two-domain, three-
protein interaction is an area worthy of future research.  
 Al of the early identified postsynaptic interactions with neuroligins (discussed 
above) involved their c-tails; however, recent studies show that their extracelular 
domains are also involved in cis interactions in the postsynaptic cel. For example, the 
ectodomains of NLGN1 and GluN1 interact, and NLGN1 binding acts as a shutle to 
deliver NMDA receptors to the synapse (Budreck et al., 2013). This binding is 
noteworthy because a phenotype of the NLGN1-/- is reduced NMDA curents (Blundel et 
al., 2010), suggesting a model where NLGN1 can directly interact with a glutamate 
receptor and afect synaptic strength, in contrast to the canonical model in which 
scafolding molecules (such as PSD-95, S-SCAM, and gephyrin) link neuroligins to the 
receptors at the synapse. A diferent ectodomain association between NLGN2 and 
MDGA1 (MAM domain-containing GPI anchor protein) breaks the intercelular 
interaction between NLGN2 and neurexin, inhibiting NLGN2-mediated presynaptic 
diferentiation (Lee et al., 2013; Petem et al., 2013). The binding sites within the 
extracelular domains of NLGN1 and NLGN2 that are required for these interactions 
remain an enigma, but these studies provide evidence that neuroligin ectodomains’ 
responsibility is not only for dimerization and to trans-synapticaly interact with 
neurexins. 
 It is likely that the library of neuroligin interacting proteins wil continue to 
expand. Two independent screens identified many proteins that interact with NLGN2 and 
NLGN3 c-tails, and these interactions have yet to be characterized (Poulopoulos et al., 
2009; Shen et al., 2015). Moreover, a critical region was identified in the c-tails of 
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NLGN1 and NLGN3 that is required for these molecules to potentiate excitatory synaptic 
transmission (Shipman et al., 2011) without a known direct binding partner (Figure 2-1). 
Additionaly, a motif in the c-tail of NLGN1 required for dendritic sorting has been 
uncovered (Figure 2-1), but the molecular basis of this traficking pathway is unknown 
and likely requires unidentified interacting proteins (Rosales et al., 2005). A subset of the 
known molecular constituents of an excitatory and an inhibitory synapse are modeled in 
Figure 1-1, with a focus on the proteins that interact with neuroligins, providing context 





















Figure 2-1. Neuroligin Cytoplasmic Domain Comparison. Alignment of the 
transmembrane and cytoplasmic domains of human neuroligins. Residues identified in 
rodent neuroligins are depicted on the analogous residues on the human isoforms for 
comparison purposes. Mapped residues and motifs are boxed. The autism mutation in 
NLGN4X is arginine (R) 704 mutated to a cysteine and in NLGN4Y isoleucine (I) 679 
mutated to a valine. The critical region is necessary for neuroligin-mediated excitatory 
synaptic potentiation. (abbreviations: Ca2+/calmodulin-dependent protein kinase I 









When comparing protein-interacting domains in the cytoplasmic-domain of 
neuroligin, it is remarkable that reductionist-binding assays show litle to no diferences 
in binding afinities between neuroligin subtypes. How do distinct neuroligin isoforms 
recruit diferent postsynaptic machinery? Although the answer stil largely remains a 
mystery, recent research suggests that phosphorylation may, at least in part, underlie 
isoform-specific regulation.  
NLGN1-mediated enhancement of excitatory synapses, for instance, has been 
shown to depend on synaptic activity, and more specificaly, phosphorylation by CaMKI 
(Bemben et al., 2014; Chubykin et al., 2007). NLGN1 is dynamicaly and transiently 
phosphorylated by CaMKI at residue T739 folowing synaptic activity or sensory 
experience in the brain (Figure 2-1). Blocking phosphorylation of this site drasticaly 
decreases the surface expression of NLGN1, thereby reducing its ability to stimulate 
synaptogenesis (Figure 2-2A). Interestingly, CaMKI has also been shown to promote 
the cleavage of NLGN1(Peixoto et al., 2012; Suzuki et al., 2012). However, an alternate 
reading is that synaptic activity may promote the cleavage of NLGN1 indirectly by 
promoting surface expression (through phosphorylation by CaMKI), which increases 
access to the protease. The phosphorylated residue, T739, is not conserved in NLGNs 2 
and 3. However, the CaMKI site is conserved in human NLGN4 and can be 
phosphorylated in vitro (Figure 2-1). This phosphorylation provides a transient and 
isoform-specific mechanism by which NLGN1 can induce synapse formation or 
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modification in response to synaptic activity and discussed in detail in Chapter 3 
(Bemben et al., 2014). 
 Not only does phosphorylation modulate NLGN1 surface expression but it also 
regulates key protein interactions. NLGN1 has a second phosphorylation site within the 
gephyrin-binding domain at Y782 (Figure 2-1), which, when phosphorylated by an 
unknown kinase, blocks the NLGN1-gephyrin interaction (Giannone et al., 2013). It has 
been proposed that neurexin1β binding to NLGN1 stimulates phosphorylation at Y782, 
thereby shifting NLGN1 assembly with excitatory (e.g. PSD-95) from inhibitory 
scafolding molecules (Figure 2-2B). These findings hint at how NLGN1 can specificaly 
recruit excitatory postsynaptic machinery even though it contains a conserved gephyrin-
binding domain. Proline-directed phosphorylation on NLGN2 S714-P (S713 in the 
human alignment, Figure 2-1) also negatively regulates its ability to bind gephyrin 
(Antoneli et al., 2014). Although this residue is not within the gephyrin-binding domain, 
like Y782 in NLGN1, phosphorylation at S714 recruits the enzyme Pin1 (peptidyl-proly 
cis-trans isomerase), which isomerizes NLGN2 and breaks its association with gephyrin 
(Figure 2-2C). Blocking phosphorylation leads to increased NLGN2-gephyrin binding, 
which results in more synaptic GABA receptors. In both studies, phosphorylation was 
only tested on NLGN1 Y782 or NLGN2 S714, but the analogous tyrosine and serine 
residues are conserved among al neuroligins (Figure 2-1). To conclude whether these 
are neuroligin isoform-specific mechanisms, it wil be necessary to look at the 




Although most of the previously discussed phosphorylation studies have focused 
on NLGN1 and NLGN2, it is NLGN3 and NLGN4 that have been most closely 
associated with disease. Might disease-associated mutations in neuroligin impact 
phosphorylation? Point mutations in NLGN3 and NLGN4 have been discovered in 
patients with autism spectrum disorders (Jamain et al., 2003; Laumonnier et al., 2004; 
Lawson-Yuen et al., 2008). However, only a single mutation has been identified thus far 
in the c-tail, NLGN4X R704C, whereas the other mutations reside in the extracelular and 
transmembrane domains (Yan et al., 2008; Yan et al., 2005) (Figure 2-1). Due to the lack 
of conservation of rodent and human NLGN4, some researchers have atempted to study 
this mutation in NLGN3, where the analogous arginine is conserved, but a knock-in 
mutation resulted in only minor synaptic efects (Etherton et al., 2011). 
Human NLGN4X is phosphorylated at T707 by PKC (Bemben et al., 2015a) 
(Figure 2-1). Intriguingly, T707 resides only a few amino acids away from the disease-
associated mutation, R704C, which, when present, completely abolishes T707 
phosphorylation, thus identifying R704 as a critical residue in a PKC consensus motif in 
NLGN4X (Figure 2-1). A phospho-mimetic mutation at T707 enhanced synaptogenesis. 
The mechanism behind this enhancement is unknown, but was not a result of changes in 
NLGN4X surface expression. It is discussed in detail in Chapter 4. It may be a result of 
a novel protein interaction on phosphorylated NLGN4X that induces the recruitment of 
glutamatergic receptors or increases recruitment of presynaptic terminals (Figure 2-2D). 
Notably, the analogous threonine in NLGN4X is not conserved in NLGN3, possibly 
explaining why the NLGN3 knock-in mutation had minor synaptic efects (Etherton et 
al., 2011) (Figure 2-1). Furthermore, the R704C mutation has diferent efects in NLGN3 
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and NLGN4X underscoring the importance of studying a disease mutation in its corect 
isoform (Chanda et al., 2015). As with al these sites, a beter understanding of when the 
phosphorylation occurs, by which kinases, and in which brain regions wil shed light on 





































Figure 2-2. Regulation of Neuroligins by Phosphorylation. A. NLGN1 pT739. (1) 
Synaptic activity drives calcium influx thereby activating CaMKI. (2) CaMKI 
phosphorylates NLGN1, which leads to increased surface expression. (3) Increased 
NLGN1 surface expression promotes the creation of new synapses. B. NLGN1 pY782. 
Phosphorylation by an unknown kinase in the gephyrin-binding domain (Y782) drives 
NLGN1 to release from gephyrin and localize at excitatory synapses as opposed to 
inhibitory synapses. C. NLGN2 pS714. (1) An unknown kinase phosphorylates NLGN2 
at S714. (2) Phosphorylation leads to recruitment and binding of Pin1. (3) Pin1 
isomerizes NLGN2, which negatively afects the NLGN2-gephyrin interaction. D. 
NLGN4X pT707. (1) Activation of PKC phosphorylates NLGN4X at T707. 



































through an unknown protein interaction (2A) or by increasing the recruitment of 
presynaptic terminals (2B). (abbreviations: α-amino-3-hydroxy-5-methyl-4-isoxazole 
propionic acid receptor (AMPAR); Ca2+/calmodulin-dependent protein kinase I 
(CaMKI); N-methyl-D-aspartate receptor (NMDAR); phosphorylation (P); protein 







































 In addition to phosphorylation of the cytoplasmic domain, diferential 
glycosylation may also play a role in modulating neuroligin activity. In the same screen 
that identified NLGN1 as a binding partner of neurexin1β, extensive glycosylation was 
also evident. The predicted molecular weight of NLGN1 is 95 kDa, but it was found to 
migrate at approximately 116 kDa (Ichtchenko et al., 1995). Bands at both apparent 
molecular weights are observed when NLGN1 is expressed in heterologous cels and 
analyzed in the brain (Song et al., 1999). Researchers used glycosidases to show the 
diference in predicted and expected size was predominantly a result of glycosylation 
(Comoleti et al., 2003; Ichtchenko et al., 1995). Structural characterization of the 
extracelular domain of NLGN1 by mass spectrometry identified five N-glycosylated and 
two O-glycosylated sites; however, insuficient coverage was seen in the highly 
glycosylated stalk region, which may lead to an underestimate of O-glycosylated sites 
(Hofman et al., 2004). N-glycosylation at any of these five sites decreases binding to 
neurexinβ, yet individual mutants are stil able to induce synaptogenesis. Interestingly, 
one of the N-glycosylation sites occurs in the β insertion of NLGN1 (N303), which is the 
alternatively spliced insert that dictates its neurexin binding preferences and its ability to 
potentiate excitatory synapses. Blocking glycosylation at this site (N303A) alows 
NLGN1 to morphologicaly enhance inhibitory synapses,(Chih et al., 2006) revealing the 
critical importance of glycosylation in isoform specificity. No disease-related mutations 
have yet been identified in neuroligins that directly afect a glycosylation site. However, 
two autism mutations (NLGN4X: R87W & NLGN3: R451C) have diferential 
glycosylation paterns when compared to WT protein resulting in decreased surface 
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expression (Tabuchi et al., 2007; Zhang et al., 2009). This diferential glycosylation is 
likely a result of protein misfolding, so rather than implicating glycosylation in disease, 
they suggest that neuroligin glycosylation may be used as a marker for surface 
expression. It is likely neuroligins have isoform-specific glycosylation as only one of the 
five identified N-glycosylated sites on NLGN1 are conserved among al isoforms (N547) 






























CaMKII Phosphorylation of Neuroligin-1 












Chapter 3 entitled CaMKII Phosphorylation of Neuroligin-1 Regulates Excitatory 







Neuroligins are postsynaptic cel adhesion molecules that are important for synaptic 
function through their transsynaptic interaction with neurexins. The localization and 
synaptic efects of neuroligin-1 (NLGN1) are specific to excitatory synapses with the 
capacity to enhance excitatory synapses dependent on synaptic activity or Ca2+/CaM 
Kinase I (CaMKI). Here, we report that CaMKI robustly phosphorylates the 
intracelular domain of NLGN1. We show that T739 is the dominant CaMKI site on 
neuroligin-1 and is phosphorylated in response to synaptic activity in neurons and 
sensory experience in vivo. Furthermore, a phospho-deficient mutant (NLGN1 T739A) 
reduces the basal and activity-driven surface expression of NLGN1, leading to a 
reduction in neuroligin-mediated excitatory synaptic potentiation. Therefore we report the 
first direct functional interplay between CaMKI and NLGN1, two primary components 
























 The processing and integration of information in the brain depends on cel-to-cel 
communication. Synapses, the sites of communication, are specialized asymmetrical 
connections between neurons that alow for the eficient transfer of information. Synaptic 
formation, structure, maturation, and maintenance are sustained by a multifarious 
network of bidirectional celular adhesion molecules that span the synaptic cleft, aligning 
the presynaptic active zone and postsynaptic density. In humans, alterations that perturb 
these celular organizers are implicated in cognitive disorders, highlighting their critical 
roles at the synapse. Arguably, the best-characterized synaptic cel adhesion molecules 
are the presynaptic neurexins (NRXNs) and postsynaptic NLGNs (Bemben et al., 2015b; 
Craig and Kang, 2007; Dalva et al., 2007; Dean and Dresbach, 2006; Sudhof, 2008; 
Yamagata et al., 2003). The transsynaptic heterophilic interaction between the 
extracelular domains of NLGNs and NRXNs can induce synapse formation and 
maturation (Bemben et al., 2015b; Chih et al., 2005; Dean et al., 2003; Graf et al., 2004; 
Levinson et al., 2005; Nam and Chen, 2005; Witenmayer et al., 2009). 
 NLGNs are postsynaptic proteins that contain a single transmembrane domain, a 
large extracelular acetylcholinesterase-like domain, and a short cytoplasmic tail (c-tail) 
that includes many protein-protein interaction domains (Ichtchenko et al., 1995; Iida et 
al., 2004; Irie et al., 1997; Poulopoulos et al., 2009; Sudhof, 2008). Rodents express four 
NLGNs (NLGN1 to NLGN4). Despite high sequence conservation among isoforms, 
subcelular localization and expression paterns vary between NLGNs (Ichtchenko et al., 
1996). NLGN1 is predominantly localized to excitatory synapses, whereas NLGN2 is 
primarily confined to inhibitory synapses (Chih et al., 2005; Graf et al., 2004; Levinson et 
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al., 2005; Song et al., 1999; Varoqueaux et al., 2004). In contrast, NLGN3 is expressed at 
both types of synapses. NLGN4 is enriched at glycinergic synapses with initial studies 
focusing on the retina (Budreck and Scheifele, 2007; Hoon et al., 2011). 
 Consistent with the localization of NLGN1 at excitatory synapses, 
overexpression of NLGN1 increases evoked excitatory postsynaptic curents (EPSCs) 
and synaptogenesis (Chih et al., 2005; Chubykin et al., 2007; Ko et al., 2009b; Kwon et 
al., 2012; Shipman et al., 2011). Moreover, NLGN1 has been shown to be involved in 
diverse forms of synaptic plasticity across species (Blundel et al., 2010; Choi et al., 
2011b; Dahlhaus and El-Husseini, 2010; Jung et al., 2010; Kim et al., 2008; Shipman and 
Nicol, 2012b). NLGN1-mediated synaptic potentiation is diminished after chronic 
blockade of NMDA receptors (NMDARs) or Ca2+/CaM Kinase I (CaMKI), suggesting 
that NLGN1 function is influenced by NMDAR signaling (Chubykin et al., 2007). While 
the regulatory mechanisms of NLGN1-mediated, activity-dependent, synaptic 
enhancement are poorly understood, previous reports have implicated the c-tail in the 
proper traficking of NLGN1 to the synapse, although its terminal PDZ ligand is not 
essential (Dean et al., 2003; Dresbach et al., 2004). Moreover, induction of synaptic 
plasticity upregulates the surface expression of NLGN1 (Schapitz et al., 2010). Finaly, 
high frequency stimulation increases the mobilization and number of NLGN1 clusters in 
cultured hippocampal neurons (Gutierez et al., 2009). Taken together, these results 
strongly suggest that NLGN1 traficking and subcelular localization are governed by 
synaptic activity, but the underlying mechanisms have remained elusive. 
 Protein phosphorylation is a principal and swift regulatory mechanism in the 
organization and functional modulation of receptors at the synapse (Kim and Huganir, 
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1999). CaMKI is a major component of the excitatory postsynaptic density and a critical 
mediator of synaptic plasticity. CaMKI-mediated phosphorylation acutely regulates the 
function and traficking of postsynaptic substrates in response to synaptic activity 
(Lisman et al., 2002). Although NLGN1-mediated synaptic potentiation depends on 
CaMKI activity, the direct phosphorylation of NLGN1 by CaMKI has not been 
reported. 
 Here, we show that NLGN1 is a direct substrate of CaMKI and identify a 
phosphorylation site, T739, in the intracelular c-tail of NLGN1 that is not conserved in 
other rodent NLGN isoforms. We demonstrate that NLGN1 T739 is specificaly 
phosphorylated by CaMKI but not other known activity-dependent kinases in the 
postsynaptic density. Additionaly, T739 phosphorylation is upregulated by synaptic 
activity. A non-phosphorylatable mutant, T739A, dramaticaly reduces the basal and 
activity-induced surface expression of NLGN1 and consequently the postsynaptic actions 
of NLGN1. Importantly, this study establishes a direct functional and isoform-specific 

















NLGN1 is Phosphorylated on T739 by CaMKII in vitro. 
 NLGN1-mediated potentiation of synaptic transmission depends on CaMKI 
(Chubykin et al., 2007). Might NLGN1 be a substrate for CaMKI? The intracelular 
domain of NLGN1 contains several serine (S) and threonine (T) residues that could 
potentialy be phosphorylated by CaMKI (Figure 3-1A). An in vitro kinase assay with 
CaMKI, [γ-32P]ATP, and engineered GST-fusion proteins containing the c-tail of 
NLGN1 (amino acids 718-843) or GluA1 (positive control), revealed that NLGN1 was 
robustly phosphorylated by CaMKI as assessed by radiography (Figure 3-1A,B). 
CaMKI phosphorylation of NLGN1 and GluA1 displayed similar reaction kinetics and 
were run to saturation (Supplementary Figure 3-1A,B). We also evaluated CaMKI 
phosphorylation on the c-tails of NLGN2, NLGN3, and NLGN4 and found NLGN2 and 
NLGN3 not to be phosphorylated, whereas CaMKI phosphorylated human NLGN4, 
albeit at a much lower level than NLGN1 (Figure 3-1C), thus indicating that NLGN1 is 
the best NLGN substrate for CaMKI. 
To identify the individual phosphorylated site(s), we generated point mutations of 
S/T residues on NLGN1 that are not conserved in NLGN2 and NLGN3, and discovered 
that mutating T739 to alanine (A) dramaticaly reduced CaMKI phosphorylation (Figure 
3-D), whereas similar mutations of neighboring T residues had litle to no efect. 
Neither cAMP-dependent Protein Kinase (PKA) nor Protein Kinase C (PKC) 
phosphorylated NLGN1 in vitro as robustly as CaMKI (Figure 3-1B). Furthermore, to 
detect if PKA or PKC are able to phosphorylate NLGN1 T739, we analyzed GST-
NLGN1 folowing in vitro kinase reactions using liquid chromatography coupled to 
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tandem mass spectrometry (LC/MS/MS) and found that only CaMKI phosphorylates 
T739 (Figure 3-1E-G). Additionaly, using LC/MS/MS method, we found that CaMKI 
phosphorylates the analogous threonine in human NLGN4 (T718) as in rodent NLGN1 
T739 (data not shown), which is not surprising considering the conservation of the 
CaMKI consensus sequence in human NLGN4 and mouse NLGN1 (Figure 3-1A; see 
sequence alignment). Taken together, these results indicate that NLGN1 T739 is the 
dominant and CaMKI-specific phosphorylation site in the intracelular tail of NLGN1 


















PKC and [γ-P32]ATP and analyzed by autoradiography. Arow denotes 
autophosphorylated PKA. Total protein was visualized by CBB protein staining, and 
GST and GST-GluA1 c-tail served as negative and positive phosphorylation controls, 
respectively, in B-D. E. ETD MS/MS spectrum of phosphorylated NLGN1 peptide 730 - 
RRCSPQRTTpTNDLTHAPEEEIM - 751 found only in GST-NLGN1 fusion proteins 
incubated with ATP and purified CaMKI and not PKA or PKC. Samples were digested 
with chymotrypsin, and then analyzed using LC/MS/MS method. F. Extracted ion 
chromatogram of quadruply charged ion at m/z 681.30, which coresponds to 
phosphorylated NL-1 peptide 730 - 751, as shown in E, for GST-NLGN1 - enzyme (red), 
+ PKA (grey), + PKC (green), and + CaMKI (blue). G. Extracted ion chromatogram of 
quadruply charged ion at m/z 661.31, which coresponds to non-phosphorylated peptide 
























T739 Phosphorylation is Regulated by CaMKII in Mammalian Cels 
 To monitor the phosphorylation of NLGN1 T739 in vitro and potentialy in vivo, 
we generated a phosphorylation state-specific antibody (Ab), pT739-Ab, against residues 
735-744 (Figure 3-1A). The specificity of pT739-Ab was tested with an in vitro kinase 
assay in which GST-NLGN1 (wild-type or T739A), 2, 3, and 4 c-tail fusion proteins were 
incubated with ATP and CaMKI. The proteins were resolved by SDS-PAGE, and 
immunobloting revealed that the phosphorylation state-specific Ab specificaly 
recognized only the NLGN1 c-tail that is phosphorylated on T739 (Figure 3-2A). 
Importantly, the non-phosphorylatable mutant (T739A), as wel as any of the other 
NLGN isoforms subjected to the same in vitro kinase assay, showed no immunoreactivity 
with pT739-Ab, highlighting the specificity of pT739-Ab for phosphorylated NLGN1 
T739. It is noteworthy that phosphorylated human NLGN4 was not eficiently detected 
by pT739-Ab, which reveals that either NLGN4 T718 is not robustly phosphorylated by 
CaMKI or pT739-Ab is, indeed, specific for phosphorylated NLGN1 T739. Regardless, 
the CaMKI consensus sequence (RXXT) in NLGN1 and human NLGN4 is completely 
divergent in rodent NLGN4, and therefore would not be detected in rodent lysate 
preparations and not a concern in this study (Boliger et al., 2008). We chose human 
NLGN4, as it is exclusively used in the literature due to its implications in cognitive 
disorders (Sudhof, 2008). 
 To test whether the ful-length NLGN1 protein is phosphorylated in intact cels 
and modulated by CaMKI activity, we transfected NLGN1 wild-type (WT) or T739A in 
COS-7 cels. Immunoblots of cel lysates probed with pT739-Ab indicated that NLGN1 
was phosphorylated on T739 under basal conditions and that no signal was observed with 
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the phospho-deficient mutant (Figure 3-2B). However, after cotransfection with a 
constitutively active form of CaMKI (T286D) or folowing incubation with KN93 (a 
CaMKI inhibitor), the basal level phosphorylation of NLGN1 T739 robustly increased or 
decreased, respectively (Figure 3-2B). Analogous regulation was observed in HEK293T 







Figure 3-2. NLGN1 T739 is Phosphorylated by CaMKII in vitro as Detected by 































































































































(WT or T739A), NLGN2, NLGN3, and NLGN4 were phosphorylated in vitro with 
purified catalytic subunits of CaMKI and analyzed by immunobloting with pT739-Ab. 
Equal loading of protein was confirmed by immunobloting with GST-Ab. B. NLGN1 
(WT or T739A) was transfected in COS cels and treated with a CaMKI inhibitor, 
KN93, or co-transfected with a constitutively active CaMKI (T286D). C. Co-
transfection of NLGN1 (WT or T739A) with CaMKI (T286D) in HEK293T cels. 


































T739 Phosphorylation is Regulated by Synaptic Activity and CaMKII in Neurons 
 The in vitro and in situ results described thus far demonstrate that CaMKI can 
phosphorylate NLGN1 T739. To test whether this phosphorylation occurs in neurons, we 
measured NLGN1 T739 phosphorylation in cultured cortical neurons after 21 days in 
vitro (DIV) and found a specific band at approximately 120 kDa, the estimated molecular 
weight of ful-length, mature NLGN1 (Figure 3-3A) indicating basal phosphorylation of 
this site in neurons. The band was dramaticaly reduced when cultures were pre-infected 
with a lentiviral shRNA against NLGN1, demonstrating the specificity of the Ab in 
neurons. Importantly, total NLGN3 protein levels were not reduced, underscoring the 
specificity of the NLGN1 knockdown.  
To examine if T739 phosphorylation is modulated by synaptic activity, we 
enhanced synaptic activity by treating cortical cultures with bicuculine (BCC), a 
GABAAR antagonist, for 2 hours (hr), which induced a 7-fold increase in NLGN1 T739 
phosphorylation relative to a DMSO control (Figure 3-3B,C). The induction of 
phosphorylation with BCC was eficiently blocked with an hour pre-treatment of AP5 
and NBQX, NMDA and AMPA receptor antagonists, respectively (Figure 3-3B,C), thus 
indicating NLGN1 T739 phosphorylation is dynamicaly regulated by changes in 
neuronal activity. Interestingly, BCC treatment also caused a reduction in total NLGN1 
protein that was prevented with AP5/NBQX pretreatment (Figure 3-3D), a likely result 
of NLGN1 N-terminal shedding, as previously observed (Peixoto et al., 2012; Suzuki et 
al., 2012). 
Next, we explored if CaMKI phosphorylates NLGN1 T739 in neurons. To 
examine this possibility, we used a KD approach in cultured cortical neurons and found 
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that a 75% reduction in CaMKI levels resulted in a 60% reduction in pT739 levels 
without efecting total NLGN1 levels (Figure 3-3E-G). Taken together with our in vitro 
and in situ results, this indicates that CaMKI is the dominant kinase that phosphorylates 
NLGN1 T739 in neurons.  
Finaly, to investigate if T739 phosphorylation occurs in vivo, we 
immunoprecipitated (IP) phosphorylated NLGN1 from WT and NLGN1 KO brains and 
detected a 120 kDa band only in the WT brain (Figure 3-3H). This band indicates that a 
subset of endogenous NLGN1 is phosphorylated at T739 in an intact mouse brain. 
Colectively, these data highlight that NLGN1 T739 is phosphorylated in live animals 



















Figure 3-3. Phosphorylation of NLGN1 T739 in Neurons. A. Detection of NLGN1 
T739 phosphorylation in DIV 21 cortical neurons with or without expression of a 
lentiviral shRNA, scrambled or targeting NLGN1. B. Regulation of NLGN1 T739 
phosphorylation under control conditions (DMSO) or in the presence of bicuculine 
(BCC) -/+ pretreatment of AP5/NBQX in DIV 21 cortical neurons. Immunoblots were 






















































































































































































































































normalized to DMSO control (n = 7) with AP-5/NBQX pretreatment + BCC (P > 0.05, n 
= 4), or BCC treatment (P < 0.0006, n = 7). D. Means ± SEM of total NLGN1 normalized 
to actin control (n = 7) with AP5/NBQX pretreatment + BCC (P > 0.05, n = 4), or BCC 
treatment (P = 0.0156, n = 7). E. Detection of NLGN1 T739 phosphorylation in DIV 21 
cortical neurons with or without expression of a lentiviral shRNA, scrambled or targeting 
CaMKI. F. Means ± SEM of phosphorylated to total NLGN1 normalized to no virus 
treatment (n = 4) with scrambled KD (P > 0.05, n = 4), or CaMKI KD (P = 0.0286, n = 
4). G. Means ± SEM of total CaMKI normalized to actin control (n = 4) with scrambled 
KD (P > 0.05, n = 4), or CaMKI KD (P = 0.029, n = 4). H. Detection of NLGN1 T739 
phosphorylation in adult WT or NLGN1 KO brains. Arows denote NLGN1 specific 



















Mutation of T739 to A Negatively Regulates the Traficking of NLGN1 
 Does T739 function in the traficking of NLGN1 to the cel surface? We 
examined the surface expression of NLGN1 (WT or T739A) expressed in cultured 
hippocampal neurons with immunofluorescence confocal microscopy. As previously 
described, we performed these experiments on a triple knockdown background to reduce 
endogenous NLGNs using exogenous chained microRNAs against NLGN1, NLGN2, and 
NLGN3 (NLmiRs), to prevent the potential masking of NLGN mutation phenotypes by 
dimerization with WT protein (Shipman et al., 2011). Surface and intracelular receptors 
were labeled with an anti-hemagglutinin (HA) tag that was inserted downstream of the 
signal peptide on NLGN1. Remarkably, T739A greatly reduced the surface expression of 
NLGN1 (Figure 3-4A,B) suggesting that phosphorylation regulates NLGN1’s forward 
traficking or stabilization at the plasma membrane.   
 
NLGN1 T739A reduces functional synapses 
 Does T739 phosphorylation function in NLGN1-mediated synaptogenesis, by 
regulating NLGN1 surface expression? To examine this possibility, we used 
immunofluorescence confocal microscopy and coexpressed NLGN1 (WT or T739A) or 
GFP with NLmiRs in cultured hippocampal neurons, and assayed endogenous VGLUT1 
and PSD-95, presynaptic and postsynaptic markers, respectively. Knockdown of 
endogenous NLGNs nearly eliminated VGLUT1 and PSD-95 staining, which resulted in 
a profound decrease in colocalization of these synaptic markers, an anatomical measure 
of synapse number (Figure 3-4C-F). Given the time course of knockdown in a 
developing neuronal culture, these results are consistent with a role of NLGNs in synapse 
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assembly or maintenance. T739A expression only partialy rescued VGLUT1 and PSD-
95 recruitment and colocalization, but to a consistently lesser extent than NLGN1 
(Figure 3-4C-E).  
Moreover, when we compared miniature postsynaptic curents (mEPSCs) in 
cultured hippocampal neurons transfected with NLmiRs + NLGN1 (WT or T739A), 
T739A did not enhance mEPSC frequency, as was seen with expression of NLGN1 
(Figure 3-4G,I). In agreement with previous results, knockdown of endogenous NLGNs 
(NLmiRs) resulted in a reduction in mEPSC frequency (Shipman et al., 2011) (Figure 3-
4G,I). Furthermore, no diference in mEPSC amplitudes was observed between NLGN1 
and NLGN1 T739A or between GFP and NLmiRs transfected cels (Figure 3-4G-I). 
Interestingly, NLGN overexpression induced a reduction in mEPSC amplitude (Figure 3-
4C,D), a likely outcome of exogenous NLGN expression increasing cel size. Together, 
these results implicate a role for T739 phosphorylation in NLGN1-mediated 
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Figure 3-4. T739A Reduces the Surface Expression and Synaptic Enhancement of 
NLGN1. A. Hippocampal neurons co-expressing NLmiRs and NLGN1 (WT or T739A). 
Surface receptors were labeled with anti-HA Ab and Alexa 555 (red) conjugated 
secondary Ab. After fixation and permeabilization, internal receptors were visualized 
with anti-HA and Alexa 647 (pseudo-colored white) conjugated secondary Ab (scale bar 
= 50 µm). B. Means ± SEM normalized to NLGN1 (n = 34) for NLGN1 T739A (P = 
0.0001, n = 36). C. Neurons transfected as in a. VGLUT1 was labeled with anti-
VGLUT1 Ab and Alexa 647 (pseudo-colored white) conjugated secondary Ab, and PSD-
95 was visualized with anti-PSD-95 and Alexa 555 (red) conjugated secondary Ab. D. 
Means ± SEM of VGLUT1 normalized to NLGN1 (n = 24) for NLmiRs (P = 0.0001, n = 
23) and NLGN1 T739A (P = 0.0001, n = 24). E. Means ± SEM of PSD-95 normalized to 
NLGN1 (n = 24) for NLmiRs (P = 0.0001, n = 23) and NLGN1 T739A (P = 0.0001, n = 
24). F. Means ± SEM of colocalized VGLUT1/PSD-95 puncta normalized to NLGN1 (n 
= 24) for NLmiRs (P = 0.0001, n = 23) and NLGN1 T739A (P = 0.0182, n = 24). G. 
Representative mEPSC traces of GFP, NLmiRs, and NLmiRs + NLGN1 (WT or T739A) 
expressing hippocampal neurons (scale bar: 15 pA/500 ms). H. Spontaneous mEPSC 
mean amplitudes ± SEM of cels transfected with GFP (n = 9), NLmiRs (P > 0.05, n = 9), 
NLmiRs + NLGN1 (P = 0.0028, n = 9), and NLmiRs + NLGN1 T739A (P = 0.0003, n = 
9) as compared to GFP transfected cels. NLGN1 T739A has no change in mEPSC 
amplitude when compared to NLGN1 (P > 0.05, n = 9). I. Spontaneous mEPSCs mean 
frequencies ± SEM of cels transfected with GFP (n = 9), NLmiRs (P = 0.0031, n = 9), 
NLmiRs + NLGN1 (P = 0.0012, n = 9), and NLmiRs + NLGN1 T739A (P > 0.05, n = 9) 
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as compared to GFP transfected cels. NLGN1 T739A reduces mEPSC frequency when 
































T739A mitigates activity-induced increases in NLGN1 surface expression   
 NLGN1 mobilization and surface expression can be dynamicaly modulated by 
high frequency stimulation and synaptic plasticity (Gutierez et al., 2009; Schapitz et al., 
2010). Does T739 phosphorylation function in activity-induced increases in NLGN1 
surface expression? To investigate this possibility, we used immunofluorescence confocal 
microscopy to compare the surface expression of NLGN1 (WT and T739A) -/+ 2 hr BCC 
treatment (the same duration used to induce T739 phosphorylation, Figure 3-3B,C) when 
expressed in cultured hippocampal neurons (analogous setup as in Figure 3-4). BCC 
induced a modest increase in NLGN1 surface expression (Figure 3-5A,B). Importantly, 
the activity-driven increase in NLGN1 surface expression was eliminated in the T739A 



















NLGN1 Induced Enhancement of Synaptic Currents is Diminished by T739A 
 Postsynaptic expression of NLGN1 results in a robust enhancement of excitatory 
postsynaptic curents (Chubykin et al., 2007; Futai et al., 2007; Shipman and Nicol, 
2012a; Shipman et al., 2011). Might T739 function in NLGN1 induced synaptic 
potentiation? To test this, we expressed NLGN1 (WT or T739A) in organotypic 
hippocampal slice cultures using sparse biolistic transfection, which alows for the 
simultaneous recording of evoked excitatory curents in both transfected and neighboring 
control cels. The magnitude of the evoked curent in the transfected cel compared to the 
non-transfected control cel functions as a readout of the experimental manipulation on 
synaptic strength. Previously, we saw no significant efect of activity block or the T739A 
mutant compared to WT upon high levels of NLGN1 expression (data not shown) 
(Shipman et al., 2011). We wondered if the high levels might have obscured any efect of 
activity and decided to reduce the expression level by placing the NLGN1 gene after the 
internal ribosomal entry site (IRES). Under reduced expression levels, NLGN1 was stil 
able to robustly potentiate both AMPAR and NMDAR curents, but interestingly, at these 
reduced levels, NLGN1 T739A did not potentiate AMPAR (Figure 3-6A,B) or NMDAR 
(Figure 3-6C,D) curents beyond those in neighboring control cels. Notably, the 
diferences in synaptic strength between NLGN1 and NLGN1 T739A are not the result of 
changes in glutamate release, as paired-pulse ratios of AMPAR curents, a measure of 
presynaptic release probability, were unchanged in the transfected cels as compared to 
untransfected cels (Supplementary Figure 3-2A-C) 
A previous report has highlighted that NLGN1-mediated postsynaptic 
enhancement is dependent on synaptic activity, and specificaly on CaMKI activation 
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(Chubykin et al., 2007). Remarkably, with the reduced expression level we now found 
that activity blockade with AP5 and NBQX mirored the diminished postsynaptic 
enhancement seen with expression of NLGN1 T739A (Figure 3-6A-D). Cels expressing 
NLGN1 T739A with the same drug treatment did not display a further decrease in 



















































































































































































































































































































































Figure 3-6. Synaptic Enhancement by NLGN1 is Reduced by Either Glutamate 
Receptor Blockade or the T739A Mutation. A. Low level postsynaptic expression of 
NLGN1 (n = 17) results in an enhancement of AMPAR-mediated curents to a greater 
extent than the expression of NLGN1 in the presence of AP5 and NBQX (P = 0.0439, n = 
15) or the expression of NLGN1 T739A (P = 0.0470, n = 12). Expression of NLGN1 
T739A in presence of AP5/NBQX did not further reduce AMPAR curents (P > 0.05, n = 
9). Ploted as percent of control (mean ± SEM), comparing transfected cels to 
simultaneously recorded, neighboring untransfected cels. Al expression is on the 
background of the NLmiRs. B. Scater plots showing individual conditions summarized 
in A. Open circles represent individual paired recordings, while filed circles represent 
means ± SEM. Traces show representative curents for each condition, with the 
transfected cel in color and the control cel in black (scale bar: 30 pA/20 ms). C. A 
similar result is shown for NMDAR-mediated curents, with a greater enhancement by 
low level postsynaptic expression of NLGN1 (n = 17) than NLGN1 expression in the 
presence of AP5/NBQX (P = 0.0363, n = 15) or the expression of NLGN1 T739A (P = 
0.0599, n = 12). Expression of NLGN1 T739A in the presence of AP5/NBQX did not 
further reduce NMDAR curents (P > 0.05, n = 7). Bar graph as in A. D. Scater plots 
showing individual conditions summarized in B. Open circles represent individual paired 
recordings, while filed circles represent means ± SEM. Traces show representative 
curents for each condition, with the transfected cel in color and the control cel in black 







Sensory-Experience Induces NLGN1 T739 Phosphorylation 
 Finaly, we examined if NLGN1 T739 phosphorylation is modulated by synaptic 
activity in vivo. Initialy, we discovered that T739 is robustly phosphorylated in the visual 
cortex, an area of sensory-evoked synaptic refinement (Philpot et al., 2001) (Figure 3-
7A). To accurately identify changes in phosphorylation levels between varying 
conditions and brain samples, we used protein lysate concentrations that did not saturate 
the amount of Ab we used to IP (Supplementary Figure 3-3A,B). To test if T739 
phosphorylation is regulated by synaptic activity in vivo, we used a wel-established dark-
rearing (DR) paradigm that involves light depriving mice for 5 days (P21-26) and re-
exposing them to light for 2 hr (DR + LR). This procedure induces anatomical, 
functional, and synaptic reassembly and refinement of cortical circuits in the developing 
visual cortex (Philpot et al., 2001; Tropea et al., 2010). DR mice had a reduction in T739 
phosphorylation (Figure 3-7B,C) compared to their light-reared (LR) litermates. 
Furthermore, DR mice that were subjected to a 2 hr LR (DR + LR) had an increase in 
NLGN1 T739 phosphorylation when compared to LR or DR litermates (Figure 3-7B,C). 
These results show that increases or decreases in neuronal activity can modulate NLGN1 








Figure 3-7. Synaptic Activity Dynamicaly Regulates T739 Phosphorylation in vivo. 
A. Detection of NLGN1 T739 phosphorylation in adult WT or NLGN1 KO visual cortex. 
B. WT mice were either light-reared for 26 days (LR), LR to P21 then subjected to 5 days 
dark-rearing from P21-26 (DR), or LR then subjected to a 5 day dark-rearing (P21-26) 
and finaly exposed to a 2 hr light stimulus at P26 (DR + LR). When animals were LR 
they were maintained on a normal day/night cycle, whereas DR animals were in complete 
darkness for 5 days. C. Regulation of NLGN1 T739 phosphorylation in DR, LR, or DR + 
LR P26 visual cortices. Adult NLGN1 KO visual cortices served as negative controls and 
actin served as a total protein control. Non-saturating protein concentrations (0.25 mg) 
were used as described in Supplementary Figure 3-3A,B. D. Means ± SEM of 
phosphorylated (IP) to total NL-1 (input) normalized to LR control (n = 7) for DR (P = 
0.0156, n = 7) and DR + LR (P = 0.0469, n = 7). Al comparisons between conditions 
























































































































 Our findings indicate a direct and novel functional interplay between NLGN1 and 
CaMKI, two halmarks of excitatory synapses, which results in the activity-dependent 
phosphorylation of NLGN1 at residue T739. Furthermore, using a combination of 
techniques we found that a non-phosphorylatable mutant, T739A, displayed diminished 
basal and activity-induced NL-1-mediated synaptic potentiation. 
Interestingly, NLGN3, the other NLGN isoform known to localize to excitatory 
synapses, which can also dimerize with NLGN1, does not undergo the same protein 
modification. This is also the case for NLGN2, although its endogenous localization is 
restricted to inhibitory synapses (Figure 3-1C). When aligning the c-tail sequences of 
NLGN1, NLGN2, and NLGN3, the analogous residue in NLGN3 is an alanine and not a 
threonine and contains a glycine insertion within the RXXT CaMKI consensus motif of 
NLGN1. Comparably, NLGN2 contains a 12 amino acid insertion in the coresponding 
region that is not contained in NLGN1, NLGN3, or NLGN4. Therefore, the sequences of 
NLGN2 and NLGN3 are suficiently divergent from NLGN1 such that the consensus 
sequence is not conserved and is unsuitable for CaMKI phosphorylation. To the best of 
our knowledge, this represents the first reported biochemical distinction between the c-
tails of NLGN1 and NLGN3. Conventional domains on the c-tail such as the PDZ ligand 
and the gephyrin binding domain are conserved among al NLGN isoforms (Figure 3-
1A) (Poulopoulos et al., 2009). A newly discovered critical residue, important in 
regulating NLGN-mediated postsynaptic efects at excitatory synapses, is evolutionarily 
preserved between NLGN1 and NLGN3 (NLGN1 E747 and NLGN3 E740, see Figure 3-
1A) (Shipman et al., 2011). Additionaly, a recent study found Y782 as a phosphorylation 
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site on the c-tail of NLGN1 (Giannone et al., 2013). This residue is conserved among al 
NLGNs (NLGN2 Y770, NLGN3 Y772, and NLGN4 Y760, see Figure 3-1A) and may 
represent an evolutionarily conserved phosphorylation site. The significance of CaMKI 
phosphorylation of NLGN1, but not NLGN3, in this region may underscore diferences 
in synaptogenic strength, mobility, or subcelular localization between NLGN1 and 
NLGN3. Alternatively, it is possible that through dimerization with NLGN1, T739 
phosphorylation could regulate NLGN3 celular or surface localization. Al of these 
possibilities certainly deserve atention in future studies. 
 Our findings show that CaMKI phosphorylates NLGN1 T739 in vitro, in 
heterologous cels, and in neurons. PKA and PKC, two activity-dependent kinases with 
similar consensus sequences and localizations to CaMKI, are unable to phosphorylate 
NLGN1 T739 in vitro (Figure 3-1E-G). Moreover, KD of CaMKI in heterologous cels 
(Figure 3-2B) and neurons (Figure 3-3E-G) results in a dramatic decrease in T739 
phosphorylation. Likewise, overexpression of a constitutively active CaMKII in 
heterologous cels results in a dramatic increase in T739 phosphorylation (Figure 3-
2B,C). Furthermore, the previous finding that NLGN1 synaptic potentiation is 
diminished with chronic blockade of CaMKI again supports CaMKI-specific regulation 
of NLGN1 (Chubykin et al., 2007). However, we cannot definitively rule out the 
possibility other kinases phosphorylate T739. 
 In addition to the proper traficking of NLGN1 under basal conditions, there is 
literature that suggests NLGN1 mobility is upregulated folowing increases in activity, 
specificaly showing an increase in NLGN1 surface expression (Gutierez et al., 2009; 
Schapitz et al., 2010). Indeed, we were able to reproduce these findings as we detected a 
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significant rise in NLGN1 surface expression folowing elevated network activity. 
Notably this activity-triggered increase was absent for NLGN1 T739A suggestive of a 
model in which activity promotes CaMKI phosphorylation of NLGN1 T739 further 
stabilizing or inducing the forward traficking of NLGN1 to the plasma membrane. It is 
tempting to speculate that this increase in surface expression might lead to activity-
dependent synaptogenesis or spine growth. Importantly, previous methods to assess 
activity-driven NLGN1 mobility have varied in the stimuli or drug treatment protocol, 
whether plasticity was induced, and techniques to gauge surface expression (Schapitz et 
al., 2010). It is possible there are diferent mechanisms of increasing NLGN1 surface 
expression, which are examined under the varying protocols. Because of these caveats we 
wil refrain from concluding that T739 is the master switch in promoting activity-driven 
NLGN1 surface expression. Additionaly, there may be activity-dependent mechanisms 
independent of increasing NLGN1 surface expression that contribute to NLGN1’s 
activity-dependent potentiation. These possibilities, taken together with our results, stil 
lead us to conclude that T739A is a prominent modulator of activity-induced NLGN1 
surface expression. 
 The molecular mechanism that regulates NLGN1 surface expression through 
CaMKI phosphorylation of T739 stil remains to be elucidated. The substitution of T739 
to an alanine (phospho-deficient mutation) decreased the forward traficking or 
stabilization of NLGN1 at the cel surface. Thus suggesting that phosphorylation could 
promote a protein-protein interaction or break a retention interaction in the secretory 
pathway thereby promoting or stabilizing NLGN1 at the plasma membrane. The 
substitution of T739 to an aspartate also reduced surface expression of NLGN1 (data not 
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shown). This supports a dynamic role for T739 phosphorylation and is consistent with the 
non-phosphorylated threonine being critical at some stage of the traficking process. 
Alternatively, the phospho-mimetic may be unable to stericaly mimic the phospho 
group, as is often seen in the literature (Esteban et al., 2003).  
A previous report by our group failed to see an activity-dependent effect on 
NLGN1 induced potentiation in organotypic slice cultures (Shipman et al., 2011). A key 
distinction between the prior and curent study is that we previously used high expression 
levels of NLGN1, whereas in the curent study we reduced total NLGN1 expression 
levels and now observed a significant activity-dependent efect of NLGN1, as wel as a 
decrease in postsynaptic curents by T739A both of which were not observed upon high 
expression levels. These results suggest that relative NLGN levels may be critical when 
assessing traficking or phenotype of other NLGN mutations. Furthermore, this may 
underlie apparent inconsistencies in the literature that varied in promoter strength, 
method, and eficiency of plasmid entry.   
Recent studies have identified an activity-dependent proteolytic cleavage of the 
extracelular domain of NLGN1 that is regulated by the activation of NMDAR and 
subsequently CaMKII (Peixoto et al., 2012; Suzuki et al., 2012). How might CaMKI, or 
synaptic activity more generaly, induce increases in NLGN1 surface expression and 
cleavage? In the present study, NLGN1 cleavage was not directly assessed, but we did 
observe a reduction in endogenous NLGN1 protein after 2 hr BCC treatment that was 
blocked in the presence of AP5/NBQX (Figure 3-3B,D) with the most conceivable 
explanation being activity-induced NLGN1 cleavage. As previously discussed, if network 
activity (a mechanism to activate CaMKI) promotes the surface expression of NLGN1, it 
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would present matrix metaloprotease 9 (MMP9) more NLGN1 substrate on the plasma 
membrane to cleave. Although increasingly complex hypotheses of how activity can 
regulate both NLGN1 surface expression and cleavage are plausible, we deem this 
explanation to be the most parsimonious based on the literature and our results.   
 The relationship between NLGNs and the etiology of autism remains unclear. 
Mutations in the extracelular domains of NLGN3 and NLGN4 have been associated with 
the disease with a sole mutation found in the cytoplasmic tail of NLGN3 (Etherton et al., 
2011; Jamain et al., 2003; Yan et al., 2005). Although we cannot directly relate NLGN1 
T739 phosphorylation to the pathogenesis of autism, the principle of postranslational 
modifications modulating NLGN function and subcelular localization may indirectly 
contribute to the pathology. Interestingly, NLGN3 R451C, the most intensely studied 
NLGN autism mutation, displays secretory traficking deficits and is retained in the 
endoplasmic reticulum, thus underlining the importance of the proper targeting of 
NLGNs and the drastic phenotypes seen by a single point mutant on the localization 
(Comoleti et al., 2004). We believe our findings elucidate a new avenue of future 
research, which may focus on how point mutations afect postranslational modifications 
that perturb NLGN function. 
 Our present results further advance the NLGN field and introduce a compeling 
new acute and local mechanism of NLGN regulation, protein phosphorylation. Although 
protein phosphorylation has been shown to positively or negatively regulate numerous 
neuronal proteins, this is the first isoform-specific phosphorylation site described on any 
NLGN protein. Such a mechanism of regulation may also be observed in other NLGN 
isoforms or in other recently discovered postsynaptic organizer molecules such as 
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LRRTMs and may contribute to isoform specificities seen in imaging and 
electrophysiological experiments (Linhof et al., 2009). Furthermore, the expanding 
association of NLGNs with cognitive disorders, particularly implications of improper 
NLGN traficking, leads one to speculate that beter understanding of NLGN function 
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MATERIALS and METHODS 
Plasmids, Antibodies, and Neuronal Cultures. Mouse pCAG-HA-NLGN1 (or T739A)-
IRES-mChery, pCAG-eGFP, pCAG-NLmiRs-GFP, and pCMV-CaMKI T286D 
plasmids were used for biochemical, electrophysiological (dispersed hippocampal 
cultures), and imaging experiments (Shipman et al., 2011). pCAG-IRES-NLGN1 (or 
T739A), in which the protein was subcloned under IRES to reduce expression, was used 
for organotypic slice culture experiments. Al NLGN1 constructs were RNAi proof as 
described previously (Shipman et al., 2011). Point mutations were made using PCR-
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based mutagenesis (QuikChange Site-Directed Instruction Manual). The primers used to 
construct NLGN1 T737A were Forward (FOR) 5’-GTGCAGCCCTCAGCGCGCGACC 
ACCAACGACCTAAC-3’ and Reverse (REV) 5’-GTTAGGTCGTTGGTGGTCG 
CGCGCTGAGGGCTGCAC-3’, NLGN1 T738A were FOR 5’-GCAGCCCTCAGCG 
CACGGCCACCAACGACCTAACCC-3’ and REV 5’-GGGTTAGGTCGTTGT 
GGCCGTGCGCTGAGGGCTGC-3’, and NLGN1 T739A were FOR 5’-CTCAGCGC 
ACGACCGCCAACGACCTAACC-3’ and REV 5-’GGTTAGGTCGTTGGCGGTC 
GTGCGCTGAG-3’. GST c-tail constructs were amplified with synthetic primers 
containing EcoR1 and XhoI flanking regions from pCAG-NLGN1 (mouse), NLGN2 
(rat), NLGN3 (human), and NLGN4 (human) plasmids and subcloned into the 
glutathione S-transferase (GST) fusion vector pGEX-6P-1 (GE Healthcare). To generate 
the phosphorylation state-specific antibody (pT739-Ab), rabbits were immunized with a 
synthetic phosphopeptide Ac-CQRTT(pT)NDLTH-amide coresponding to amino acids 
735-744 of NLGN1 generated by New England Peptide. Sera were colected and afinity-
purified with an antigen-phosphopeptide. Al immunobloting using NLGN1 T739-Ab 
began with an hour blocking in 5% PhosphoBLOCKER (CELL BIOLABS, INC) at room 
temperature, folowed by 1% PhosphoBLOCKER in the primary and secondary Ab 
incubations. Antibodies used in the study were anti-NLGN1 4C12 (Synaptic Systems, 
1:1000), anti-GST (Bethyl Laboratories, 1:50000), anti-HA rat (Roche, 1:1000), anti-HA 
rabbit (Abcam, 1:1000), anti-NLGN3 (Neuromab, 1:1000), anti-CaM Kinase I (Thermo 
Scientific, 1:1000), anti-PSD-95 (Neuromab, 1:1000), anti-VGLUT1 (Milipore, 1:5000) 
and anti-actin (ABM, 1:5000). Primary cultured neurons were isolated from E18 
Sprague-Dawley rats. Cortical neurons were used for biochemical experiments as the 
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cortex provides suficient material for protein analysis. Hippocampal cultures were used 
for immunocytochemistry and electrophysiology experiments. The use and care of 
animals used in this study folowed the guidelines of the NIH Animal Research Advisory 
Commitee. 
GST-Fusion Protein Production and In Vitro Phosphorylation. Using the protocol 
provided by GE Healthcare, GST-fusion proteins were purified from BL21 bacterial cels 
transformed with pGEX-NLGN1 NLGN2, NLGN3, NLGN4, or GluA1. 50-ml cultures 
were grown at 37°C to A600=1.1-1.2 after adding 1 ml of overnight cultures. To induce 
protein expression, 50 uM IPTG was added to the cultures, and they were grown at 16°C 
for 10-12 hr. The cels were then lysed with a sonicator in a TBS bufer containing 
protenase inhibitors (Roche), 100 ug/ml lysozyme, 1 mM DTT, and 0.2 mM EDTA. The 
sonicated lysate was incubated with a 10:1 ratio with glutathione-Sepharose 4B (GE 
Healthcare) for 1 hr at 4°C and subsequently washed extensively with TBS bufer. For 
PKA in vitro phosphorylation, GST-fusion proteins were phosphorylated in 10 mM 
HEPES (pH 7.0), 20 mM MgCl2, 50 µM ATP, 1 pmol of [γ-
32P]ATP (3000 Ci/mmol) 
with 50 ng of purified PKA catalytic subunit (Promega). For PKC phosphorylation, 
reactions were performed in 20 mM HEPES, pH 7.4, 1.67 mM CaCl2, 1 mM DTT, 10 
mM MgCl2, 50 µM ATP, 1 pmol of [γ-
32P]ATP (3000 Ci/mmol) with 10 ng of purified 
PKC (Promega). For CaMKI phosphorylation, reactions were executed in 20 mM Tris-
HCl (pH 7.5), 10 mM MgCl2, 0.5 mM DTT, 0.1 mM EDTA, 2.4 µM calmodulin, 2 mM 
CaCl2, 100 µM ATP, 1 pmol of [γ-
32P]ATP (3000 Ci/mmol) with 25 ng of recombinant 
CaMKIα (Calbiochem). Al in vitro kinase assays were performed at 30°C for 30 
minutes (min), except when otherwise stated. The reactions were halted with addition of 
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SDS-PAGE sample bufer and incubation at 65°C for 5 min. The proteins were resolved 
by SDS-PAGE and visualized by autoradiography. For in vitro kinase assays analyzed by 
immunoreactivity, SDS-PAGE separated proteins were transfered to PVDF membranes 
and assayed for phosphorylation (or total protein) by immunobloting with their 
respective antibodies. 
Mass Spectrometry. Samples were alkylated with iodoacetamide, digested with 
chymotrypsin overnight at 25°C. Peptides were analyzed by a nano-LC/MS/MS system 
with an Ultimate 3000 HPLC (Thermo-Dionex) connected to an Orbitrap Elite mass 
spectrometer (Thermo Scientific) via an Easy-Spray ion source (Thermo Scientific). 
Peptides were separated on ES800 Easy-Spray column (75 µm inner diameter, 15 cm 
length, 3 µm C18 beads; Thermo Scientific) at a flow rate of 300 nl/min with a 25 min 
linear gradient of 2–27% mobile phase B (mobile phase A: 2% acetonitrile, 0.1% formic 
acid; mobile phase B: 98% acetonitrile, 0.1% formic acid). Thermo Scientific Orbitrap 
Elite mass spectrometer was operated in positive nano-electrospray mode. MS data were 
acquired in both profile and data dependent modes. The resolution of the survey scan was 
set at 60k at m/z 400 with a target value of 1×106 ions. The m/z range for MS scans was 
300–2000. The isolation window for MS/MS fragmentation was set to 1.9 and the top 
two most abundant ions were selected for product ion analysis. Ion trap enhanced scan 
rate was used for the MS/MS data acquisition with decision tree procedure activated. 
Dynamic exclusion was 9 seconds and early expiration was abled. Xcalibur RAW files 
were converted to peak list files in mgf format using Mascot Distiler (version 2.4.3.3). 
Database search was performed using Mascot Daemon (2.4.0) against a house-built 
database containing NCBI human sequences and GST-NLGN1 sequence. 
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Immunobloting. HEK293T or COS cels were transfected using Liptofectamine 2000 
Reagent (Invitrogen). 1-2 days folowing transfection, cels were washed in PBS and 
colected in a TBS bufer containing 150 mM NaCl, 50 mM Tris-HCl, 1 mM EDTA, 
protease (Roche), and phosphatase (Sigma) inhibitors. After centrifugation, peleted cels 
were lysed directly with SDS-PAGE sample bufer and subjected to Western bloting. 
KN93 (Tocris) or DMSO (Sigma) treatment occured 2 hr before cel isolation. DIV 21 
cortical neurons were isolated and lysed with the same protocol as HEK293T and COS 
cels. Treatment with 40 µM bicuculine (Tocris) or DMSO began 2 hr before cel 
isolation or an hour after AP5 (Tocris) and NBQX (Tocris) treatment. For brain IPs, WT 
or NLGN1 KO brains were homogenized in TEVP bufer (20 mM Tris (pH 7.5), 0.32 M 
sucrose, 5 mM EDTA, and protease and phosphatase inhibitors). Homogenates were 
centrifuged at 800g for 10 min, then the nuclear pelet was discarded and the supernatant 
was centrifuged at 9400g for 15 min. The P2 membrane fraction was resuspended in 
TEVP bufer supplemented with 1% SDS and 150 mM NaCl, gently sonicated, and 
incubated at 37°C for 15 min. The lysate was then neutralized with 10-fold TEVP bufer 
supplemented with 2% triton x-100 and 150 mM NaCl for a minimum of 15 min at 4°C. 
The neutralized lysate was incubated with pT739-Ab and protein A-Sepharose beads (GE 
Healthcare) at 4°C overnight. Samples were immunobloted with NLGN1 4C12 Ab after 
3 washes in TEVP bufer. To knockdown NLGN1 or CaMKI in neurons, we subcloned a 
short hairpin targeting the rodent NLGN1 sequence GGAAGGTACTGGAAATCTATA 
(previously characterized) (Chih et al., 2005) or CaMKI sequence TCCTCTGAGAGCA 
CCAACA under the ubiquitin promoter in a FUGW lentivirus vector. To produce the 
virus, the hairpin targeting vector, a viral packaging vector, and a VSVG envelope vector 
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were co-transfected into HEK-293FT cels using FUGENE (Roche). Supernatants were 
colected 48 h after transfection, centrifuged at 82,000g to pelet the lentivirus, and 
resuspended in phosphate-bufered saline. Cortical neurons (6-wel dish) were infected 
with 3-5 µL of concentrated virus for 7-10 days.  
Immunocytochemistry. Cultured hippocampal neurons (DIV 10-12) were grown on 
glass coverslips precoated with poly-D-Lysine (Sigma) and co-transfected with NLmiRs 
and HA-NLGN1 (WT or T739A) with Liptofectamine 2000 and analyzed at DIV 14-16. 
To label surface protein, transfected live cels were labeled with anti-HA (rat) Ab for 10 
min at room temperature. Cels were washed in PBS and then fixed in 4% 
paraformaldehyde/4% sucrose in PBS for 8 min. The cels were incubated with Alexa 
555 conjugated (red) anti-rat secondary Ab (Molecular Probes). Folowing surface 
staining, cels were extensively washed and permeabilized in 0.25% TX-100, blocked in 
10% normal goat serum, and labeled with anti-HA (rabbit, 1:200) Ab. After being 
washed with PBS, cels were labeled with Alexa 647 conjugated (blue) anti-rabbit 
secondary Ab (shown in white, 1:500) and mounted with a ProLong Gold Antifade kit 
(Molecular Probes). Experiments that involved treating cultures with DMSO or 40 µM 
bicuculine had drug application 2 hr prior to surface staining. For endogenous VGLUT1 
and PSD-95 staining, cels were fixed, permeabilized, and blocked as described above. 
Then labeled with anti-VGLUT1 (guinea pig, 1:5000) and anti-PSD-95 (mouse, 1:100) 
Ab(s). Folowing primary Ab incubation, the cels were washed extensively and labeled 
with Alexa 647 conjugated (blue) anti-guinea pig secondary Ab (shown in white, 1:500) 
and Alexa 555 conjugated (red, 1:500) anti-mouse secondary Ab and mounted as 
described above. Al primary and secondary Ab incubations were performed in the 
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BioWave Pro (Pelco). Neurons were imaged with a 63X objective on a Zeiss LSM 510 
confocal microscope. For analysis, images from three dendrites per neuron from at least 
seven neurons per experiment were colected and quantitated by normalizing the 
fluorescence intensity of the surface expressed NLGN1 (or T739A) with the fluorescence 
intensity of total NLGN1 (or T739A) in each cel using MetaMorph Version 7 (Universal 
Imaging). The fluorescence intensities of VGLUT1 and PSD-95 were measured similarly 
with the number of colocalized puncta obtained from 3-4 regions of 30 µm/cel. Cel 
selection was not done in the blind and was based on positive transfection but al data 
analysis was done in the blind. Three independent experiments were performed per 
experiment, and the number of neurons (n) per condition is located in the coresponding 
figure legend. 
Electrophysiology. Whole-cel voltage clamp recordings of miniature excitatory 
postsynaptic curents (mEPSC) were performed in cultured hippocampal neurons. The 
time, duration, and co-transfection protocol are analogous to the procedures used in the 
immunocytochemistry experiments. Recordings were made at 20-25°C using glass patch 
electrodes filed with an internal solution consisting of 140 mM CsMeSO4, 5 mM NaCl, 
10 mM HEPES, 10 mM EGTA, 4 mM Mg-ATP, and 0.3 mM Na-GTP with a pH of 7.4 
and Osm of 290, and an external solution containing 140 mM NaCl, 4 mM KCl, 2 mM 
MgCl2, 2 mM CaCl2, 10 mM HEPES, 1 µM TTX, and 5 mM glucose. Co-transfected 
cels with NLmiRs and NLGN1 (WT or T739A) were visualized with fluorescence, 
mEPSCs were measured at -60 mV, and only cels with capacitances of 60 pF or above 
were analyzed to reduce variability. mEPSCs were measured ofline with customized 
software (IGOR). Dual whole-cel recordings were made similarly using an internal 
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solution containing 120 mM CsMeSO4, 20 mM CsCl, 4 mM NaCl, 10 mM HEPES, 4 
mM NaCl, 0.4 mM EGTA, 0.3 mM CaCl2, 4 mM Mg-ATP, 0.3 mM Na-GTP, and 5 mM 
QX-314, and an external solution containing 125 mM NaCl, 2.5 mM KCl, 4 mM MgCl2, 
4 mM CaCl2, 1.25 mM NaH2PO4, 25 mM NaHCO3, and 11 mM glucose bubbled 
continuously with 95%O2/5% CO2. Recordings were made in the presence of picrotoxin 
(100 µM) to block inhibitory curents at -70 mV (AMPA) and +40 mV (NMDA). 
AMPAR-mediated curents were measured at the peak of the curent, whereas NMDAR-
mediated curents were measured 100 ms after the simulation. Slices pretreated with AP5 
and NBQX had drugs washed out prior to recordings. Paired-pulse ratio was determined 
by providing two pulses separated by 40 ms. The ratio was expressed as the peak curent 
of the second EPSC over the peak curent of the first EPSC. Cel selection was not done 
in the blind and was based on positive transfection but al data analysis was done in the 
blind. At least three independent experiments were performed per condition, and the 
number of neurons per mEPSCs or dual whole-cel recordings (n) per condition is located 
in the coresponding figure legend. 
Dark Rearing Experiments. Male and female C57BL/6j litermates were either 
maintained in a traditional light dark cycle (12 hr light/12 hr dark) from P0 to P26 (LR), 
relocated to complete darkness at P21 to P26 (DR), or transfered to darkness at P21 to 
P26 and shifted back to light for 2 hr before euthanization (DR + LR). The primary visual 
cortex was macrodissected in the dark for the DR condition or in light for the LR and DR 
+ LR conditions. Homogenization of the visual cortex and NLGN1 IPs were performed 
as described in immunobloting. 
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Statistical Analysis. Statistical significance of immunoblots, immunocytochemistry, 
mEPSC, and dual whole-cel recordings were tested using a Mann-Whitney U test. Data 
distribution was assumed to not be normal. Al experiments were done at least three 
independent times. No statistical methods were used to predetermine sample sizes but our 
sample sizes are similar to those reported in the literature. Al data were colected and 




























 The folowing section contains supplemental figures describing additional data 
that was previous published (Bemben et al., 2014) that supports our conclusions from the 
Results Section. The materials and methods for these experiments are explained in the 




























Supplementary Figure 3-1. NLGN1 and GluA1 c-tails Have Similar Reaction 
Kinetics. A. GST-NLGN1 or GluA1 were incubated with purified CaMKI and [γ-
P32]ATP and analyzed by autoradiography. Reactions were stopped at their marked time. 
B. Protein concentrations are ploted as a ratio of phosphorylated NLGN1 (P-32) to total 
NLGN1 (CBB) normalized to the 1 min reaction condition. Saturation of phosphorylated 
NLGN1 and GluA1 occured at approximately 10 min. Total protein was visualized by 























Time (min): 01 0105 0510 1030 3060 60
GST-NLGN1 c-tail GST-GluA1 c-tail CaMKI +
GluA1 
NLGN1 



























Supplementary Figure 3-2. NLGN1 T739A does not Afect Presynaptic Release 
Probability. Paired-pulse ratio (PPR), second EPSC over first EPSC for consecutive 
stimuli separated by 40 ms. Example traces normalized at first EPSC for A. NLGN1. B. 
NLGN1 T739A. C. Second EPSC over first ± SEM. NLGN1 and NLGN1 T739A had 





























































Supplementary Figure 3-3. Titration of Phosphorylated NLGN1 with pT739-Ab. A. 
Protein concentrations from adult WT or NLGN1 KO brains were titrated with pT739-
Ab. B. Protein concentrations are ploted as ratio of phosphorylated (IP) to total NLGN1 
(input) normalized to the 0.2 mg protein condition for an individual brain. Saturation of 















































































Autism-Associated Mutation Inhibits Protein 
Kinase C-Mediated Neuroligin-4X Enhancement 










Chapter 4 entitled Autism-associated mutation inhibits protein kinase C-mediated 







Autism spectrum disorders (ASDs) comprise a highly heritable, multifarious group of 
neurodevelopmental disorders, which are characterized by repetitive behaviors and 
impairments in social interactions. Point mutations have been identified in X-linked 
Neuroligin (NLGN) 3 and 4X genes in patients with ASDs and al of these reside in their 
extracelular domains except for a single point mutation in the cytoplasmic domain of 
NLGN4X in which an arginine is mutated to a cysteine (R704C). Here we show that 
endogenous NLGN4X is robustly phosphorylated by protein kinase C (PKC) at T707, 
and R704C completely eliminates T707 phosphorylation. Endogenous NLGN4X is 
intensely phosphorylated on T707 upon PKC stimulation in human neurons. Furthermore, 
a phospho-mimetic mutation at T707 has a profound efect on NLGN4X-mediated 
excitatory potentiation. Our results now establish an important interplay between a 
genetic mutation, a key postranslational modification, and robust synaptic changes, 
















 In a 2014 report published by the Centers for Disease Control and Prevention 
(CDC), it was estimated that 1 in 68 children in the United States have an ASD (2014). 
These neuropsychiatric disorders have a strong genetic component consistent with high 
recurence rates between siblings and a higher concordance frequency seen in 
monozygotic than dizygotic twins. Furthermore, deletions, insertions, and substitutions 
have been identified within the genome that increase the risk of these disorders 
(Abrahams and Geschwind, 2008; Zoghbi and Bear, 2012). These cytogenetic and 
genome sequencing studies have revealed that NLGNs are one of a subset of genes 
encoding synaptic proteins associated with ASDs (Bemben et al., 2015b; Jamain et al., 
2003). 
The NLGN gene family consists of five members (Nlgn1, 2, 3, 4X, and 4Y) within 
the human genome that encode transsynaptic cel adhesion molecules that are critical for 
synapse assembly, maintenance, and plasticity (Bemben et al., 2015b; Craig and Kang, 
2007; Dean and Dresbach, 2006; Sudhof, 2008). Numerous studies have identified a 
variety of mutations in X-linked NLGN3 and 4X genes that range from copy number 
variants (Levy et al., 2011; Marshal et al., 2008; Sanders et al., 2011; Thomas et al., 
1999) to protein truncations and amino acid substitutions in patients with ASDs (Jamain 
et al., 2003; Laumonnier et al., 2004; Lawson-Yuen et al., 2008). Interestingly, al of the 
point mutations in NLGN3 and NLGN4X reside in their extracelular domains except for 
a single point mutation in the cytoplasmic domain (c-tail) of NLGN4X at arginine (R) 
704, which is modified to a cysteine (C) (Yan et al., 2005). How this mutation or other 
NLGN disease mutations contribute to the pathophysiology is unknown. 
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Protein phosphorylation is a critical modulator of NLGN function (Bemben et al., 
2014; Giannone et al., 2013). Recently, we showed that Ca2+/CaM Kinase I (CaMKI) 
phosphorylates the c-tail of NLGN1 in an isoform-specific and activity-dependent 
manner, which regulates its ability to enhance excitatory synapses (Bemben et al., 2014). 
Next, we wondered if diferent kinases might regulate the function of other NLGN 
isoforms? 
 In the present study, we show in vitro and in vivo that NLGN4X is robustly 
phosphorylated by PKC. We identified the dominant phosphorylation site as T707, a 
residue not conserved in NLGN1, NLGN2, and NLGN3. Intriguingly, PKC 
phosphorylation is eliminated with the autism-associated mutation R704C. Most 
dramaticaly, we found that the phospho-mimetic mutation at T707 profoundly enhances 
anatomical markers for synapses and potentiates NLGN4X-mediated excitatory synaptic 
transmission. This study establishes compeling evidence that NLGN4X can act at and 
regulate excitatory synapses. Furthermore, it demonstrates, strikingly, how a single point 















PKC Phosphorylates NLGN4X at T707 
 To test if NLGNs are substrates for kinases other than CaMKI, we conducted an 
in vitro kinase assay with GST-fusion constructs with the c-tails of NLGN1, NLGN2, 
NLGN3, and NLGN4X (Figure 4-1A and Supplementary Figure 4-1), and found that 
NLGN4X was robustly phosphorylated by PKC as evaluated by radiography (Figure 4-
1B). Weak phosphorylation of NLGN1 and NLGN3 was observed when compared to 
NLGN4X (Figure 4-1B, see longer exposure), indicating NLGN4X to be the best NLGN 
substrate for PKC. To identify the individual PKC phosphorylation site(s), we subjected 
NLGN4X to the same in vitro kinase assay and evaluated phosphorylation using liquid 
chromatography coupled to tandem mass spectrometry (LC-MS/MS) and identified the 
major phosphorylation site as T707 (Figure 4-1C), a residue that is not conserved in 
NLGN1, NLGN2, and NLGN3 (Figure 4-1A and Supplementary Figure 4-1 for 
complete alignment). 
Autism-Associated Mutation Eliminates PKC Phosphorylation of NLGN4X 
 Interestingly, T707 resides only a few amino acids away from the only known 
autism-associated mutation (R704C) in the c-tail of any NLGN protein (Figure 4-1A). 
This substitution replaces a positive charge for a polar amino acid, and occupies a critical 
residue in a potential PKC consensus sequence (RXXS/T, where X denotes any amino 
acid). Might the autism-related R704C mutation abolish PKC phosphorylation of 
NLGN4X at T707? To independently verify the mass spectrometry results, we performed 
the same in vitro kinase assay with a non-phosphorylatable point mutation, T707A, and 
showed that T707 was the dominant NLGN4X PKC phosphorylation site, which resulted 
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in an approximately 75% reduction in NLGN4X phosphorylation. Likewise, NLGN4X 
R704C eliminated T707 phosphorylation (Figure 4-1D,E). Importantly, CaMKI 
phosphorylation of NLGN4X T718, the only other known phosphorylation site near 
T707, was not reduced by the R704C mutation demonstrating that this mutation did not 
result in a generalized problem rendering the protein unphosphorylated (Supplementary 
Figure 4-2A,B). Taken together, these results indicate that NLGN4X is a robust substrate 
for PKC, and the only autism-associated NLGN4X c-tail mutation abolishes T707 
phosphorylation. 
 To detect NLGN4X T707 phosphorylation in vivo, we produced a 
phosphorylation state-specific antibody (Ab), pT707-Ab, against residues 703-712 in 
NLGN4X (Figure 4-1A). The pT707-Ab only detected NLGN4X that was 
phosphorylated on T707 as detected by a PKC in vitro kinase assay that was resolved by 
SDS-PAGE and subsequent immunobloting (Figure 4-1F). Criticaly, the pT707-Ab did 
not show any immunoreactivity with the non-phosphorylated NLGN4X, the non-
phosphorylatable mutants (R704C or T707A), or any of the other NLGN isoforms that 
were tested. 
 The in vitro experiments were performed with fusion proteins of NLGN c-tail 
isoforms. To test whether ful-length NLGN4X can be phosphorylated in mammalian 
cels and modulated by PKC activity, we transfected wild-type (WT) NLGN4X or 
various NLGN4X mutants (R704C, T707A, or T707D) in COS-7 cels and 
immunobloted cel lysates with the pT707-Ab. Under basal conditions, NLGN4X was 
not phosphorylated at T707, but transient activation of PKC by phorbol 12-myristate 13-
acetate (PMA) triggered a robust increase in pT707 phosphorylation (Figure 4-1G). 
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NLGN4X R704C resulted in an approximately 95% reduction in pT707 phosphorylation, 
whereas NLGN4X T707A or the phospho-mimetic mutation, T707D, were not detected 
by the pT707-Ab (Figure 4-1G,H). Phosphorylation of serine (S) 831 on GluA1 was 
used as a positive control for PMA activation of PKC (Roche et al., 1996) (Figure 4-
1G,I). Additionaly, the pT707-Ab had astonishing specificity for immunoprecipitating 
(IP) only NLGN4X phosphorylated on T707 as validated by Western bloting with two 
independent NLGN4X Abs and a pan NLGN-Ab (Supplementary Figure 4-3). 
Colectively, these data demonstrate that NLGN4X T707 is phosphorylated in 
heterologous cels, and the pT707-Ab is a dynamic and isoform- specific reagent that 








Figure 4-1. Autism-Associated Mutation Eliminates PKC Phosphorylation of 
NLGN4X. A. Alignment of the transmembrane domains and partial c-tails of human 
NLGN1, NLGN2, NLGN3, NLGN4X, and NLGN4Y. The PKC phosphorylation site, 
T707, is boxed in orange; autism mutation, R704, boxed in blue; and pT707-Ab epitope 
boxed in yelow. The CaMKI phosphorylation site on NLGN1 is boxed in gray. B,D. 
Purified PKC and [γ-P-32]ATP were incubated with GST-fusion proteins and analyzed 
by autoradiography. CBB protein staining was used to visualize total protein, and GST 
(negative) and GST-GluA1 c-tail (positive) functioned as phosphorylation controls. C. 
ETD MS/MS spectrum of chymotrypsin digested phosphorylated NLGN4X peptide 704 - 
RHETHRRPSPQ - 714 found in GST-NLGN4X fusion proteins that were incubated with 
ATP and purified PKC. Samples were analyzed using LC/MS/MS method. E. Means ± 
SEM of phosphorylated NLGN4X by PKC normalized to WT (n = 4) for NLGN4X 
R704C (P = 0.0013, n = 4) and NLGN4X T707A (P = 0.0030, n = 4). F. GST, GST-
NLGN1, NLGN2, NLGN3, and NLGN4X (WT, R704C, and T707A) were incubated 
with PKC and phosphorylation was evaluated by immunobloting with pT707-Ab. Total 
protein was evaluated with a GST-Ab. G. GFP, GluA1, or NLGN4X (WT, R704C, 
T707A, or T707D) were transfected in COS cels and treated with DMSO or PMA, a 
PKC activator. GluA1 pS831 served as control for PKC activation and the arow denotes 
the NLGN4X specific band. H. Means ± SEM of phosphorylated NLGN4X pT707 
achieved by PMA activation normalized to WT (n = 3) and NLGN4X R704C (P = 
0.0310, n = 3). I. Means ± SEM of phosphorylated GluA1 S831 achieved by PMA 
activation (P = 0.0187, n = 3) normalized to no treatment (n = 3). Immunoblots were 
probed with indicated antibodies in F,G. *P < 0.05 **P < 0.01. 
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Phosphorylation of NLGN4X at T707 Induces Synaptogenesis 
 Previously, two autism-associated mutations in NLGN3 (R451C) and NLGN4X 
(R87W) were shown to disrupt surface expression (Tabuchi et al., 2007; Zhang et al., 
2009). Moreover, phosphorylation of the NLGN1 c-tail regulates its forward traficking 
(Bemben et al., 2014). Does T707 regulate NLGN4X surface expression? To test this 
possibility, cultured rat hippocampal neurons were transfected with NLGN4X (WT, 
R704C, T707A, or T707D) and visualized with immunofluorescence confocal 
microscopy. To prevent potential heterodimerization, we performed these experiments on 
a reduced endogenous NLGN background using an exogenous chained microRNA 
against NLGN1, NLGN2, and NLGN3 (NLmiRs) as previously described (Shipman et 
al., 2011). Human NLGN4X and NLGN4Y are absent in rats (Boliger et al., 2008). 
Consequently, rat neurons were used in al imaging and physiology experiments to ensure 
a NLGN4 nul background to avoid any complications that might occur between 
dimerization of WT and mutant NLGN4 receptors. Phosphorylation at T707 did not 
afect the traficking of NLGN4X to the cel surface (Figure 4-2A,B). However, we 
noticed that expression of a phospho-mimetic mutation of NLGN4X T707 (T707D) 
resulted in a robust increase in dendritic protrusions when compared to NLGN4X WT 
and the non-phosphorylatable mutants, R704C and T707A (Figure 4-2A,C). To examine 
if the increase in spines resulted in new excitatory synapses, we co-expressed NLmiRs 
with NLGN4X (WT, R704C, T707A, or T707D) in rat hippocampal cultures and assayed 
for anatomical measures of functional synapses, namely increases in presynaptic 
VGLUT1 and postsynaptic PSD-95. Using immunofluorescence confocal microscopy, 
we found that the NLGN4X phospho-mimetic (T707D) mutation resulted in an increase 
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in both VGLUT1 and PSD-95 staining, an enhancement that was absent in non-
phosphorylated NLGN4X protein (Figure 4-2D-F). These results indicate that T707 
phosphorylation promotes NLGN4X-induced synaptogenesis independent of regulating 
its surface expression. 
To test whether these new synapses were functional, we biolisticaly co-expressed 
NLmiRs with NLGN4X (WT, R704C, T707A, or T707D) in rat organotypic 
hippocampal slice cultures and used a dual whole cel recording configuration to 
simultaneously record evoked excitatory postsynaptic curents in both transfected and 
neighboring control, untransfected cels. Expression of NLGN4X T707D resulted in a 
profound increase in both AMPA receptor (AMPAR) and NMDA receptor (NMDAR) 
mediated curents when compared to a control cel or NLGN4X (WT, R704C, or T707A) 
(Figure 4-3A-D). Previously, we, as wel as others, have reported that NLGN4X 
expression on a WT background decreased postsynaptic excitatory curents (Shipman et 
al., 2011; Zhang et al., 2009). However, on a reduced NLGN background, which alone 
reduces AMPAR and NMDAR mediated curents by about 50% (Supplementary Figure 
4- 4), NLGN4X expression induced a modest, but significant, increase in AMPAR 
transmission, an enhancement that was absent in R704C and T707A (Figure 4-3A-D). 
Together, these results show that phosphorylation at T707 dynamicaly regulates 











Figure 4-2. NLGN4X Phosphorylation at T707 Induces Synaptogenesis. A. Co-
expression of NLmiRs and NLGN4X (WT, R704C, T707A, or T707D) in rat 
hippocampal neurons. Surface and intracelular receptors were labeled with an anti-
hemagglutinin (HA) antibody, which recognized a tag inserted downstream of the signal 
peptide (scale bar = 20 µm). B. Means ± SEM normalized to NLGN4X (n = 27), 
NLGN4X R704C (P > 0.05, n = 29), NLGN4X T707A (P > 0.05, n = 30), and NLGN4X 
T707D (P > 0.05, n = 29). C. Means of spine number ± SEM normalized to NLGN4X (n 
= 30), NLGN4X R704C (P > 0.05, n = 30), NLGN4X T707A (P > 0.05, n = 30), and 
NLGN4X T707D (P = 0.001, n = 30). D. Same transfections as in A. except NLGN4X 
constructs did not contain an HA-tag. Endogenous VGLUT1 and PSD-95 were stained 
and visualized as described in Experimental Procedures. E. Means ± SEM of VGLUT1 
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T707A (P > 0.05, n = 30) and NLGN4X T707D (P = 0.0466, n = 30). F. Means ± SEM 
of PSD-95 normalized to NLGN4X (n = 30) for NLGN4X R704C (P > 0.05, n = 27), 
NLGN4X T707A (P > 0.05, n =28), and NLGN4X T707D (P = 0.0049, n = 30). *P < 































Figure 4-3. NLGN4X T707D Dramaticaly Enhances Excitatory Postsynaptic 
Currents. A. AMPAR-mediated EPSC scater plots. Expression of either NLGN4X or 
NLGN4X T707D results in a potentiation of AMPAR-mediated curents compared to 
control, untransfected cels (P = 0.0023, n = 18; P = 0.0010, n = 11). The enhancement 
was absent in NLGN4X R704C (P > 0.05, n = 13) and NLGN4X T707A (P > 0.05, n = 
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reduced NLGN background (NLmiRs). Open circles are individual pairs, filed (in red) 
are mean ± SEM. Black sample traces are control; green are transfected. Scale bars 
represent 15 pA and 10 ms. B. Summary graph of data in A. Expression of NLGN4X 
T707D resulted in a greater enhancement of AMPAR-mediated curents compared to 
NLGN4X (P = 0.0143), NLGN4X R704C (P = 0.0025), or NLGN4X T707A (P = 
0.0066). C. NMDAR-mediated EPSC scater plots. Expression of NLGN4X (n = 12) or 
phosphodeficient mutants, NLGN4X R704C (n = 11) or NLGN4X T707A (n = 13), did 
not enhance NMDAR-mediated curents compared to control untransfected cels (P > 
0.05), whereas expression of NLGN4X T707D significantly potentiated NMDA-
mediated curents (P = 0.0117, n = 9). Open circles are individual pairs, filed (in red) are 
mean ± SEM. Black sample traces are control; green are transfected. Scale bars represent 
30 pA and 20 ms. D. Summary graph of data in C. Expression of NLGN4X T707D 
resulted in a enhancement of NMDAR-mediated curents compared to NLGN4X (P = 
0.0409), NLGN4X R704C (P = 0.0250), and NLGN4X T707A (P = 0.0138). *P < 0.05 














Endogenous NLGN4X is Phosphorylated by PKC in Human Neurons 
 Because our NLGN4X pT707-Ab was so specific, we were able to investigate 
endogenous NLGN4X T707 phosphorylation in cultured human embryonic neurons. 
These cultures consisted primarily of MAP2 positive neurons (Figure 4-4A) and 
transient activation of PKC with PMA resulted in approximately an 8-fold increase in 
NLGN4X pT707 phosphorylation (Figure 4-4B,C). Consistent with previous reports, 
NLGN4X was expressed in human embryonic neurons, as detected with two independent 
NLGN4X Abs and a pan NLGN-Ab (Marei et al., 2012). Taken together, these results 
























Figure 4-4. PKC phosphorylates Endogenous NLGN4X in Human Neurons. A. 
Immunofluorescence image of human embryonic neurons stained with the neuronal 
marker MAP2. B. Regulation of NLGN4X phosphorylation at T707 in human embryonic 
neurons -/+ PMA treatment. Arow denotes the NLGN4X pT707 specific band. 
Immunoblots were probed with indicated antibodies. C. Means ± SEM of phosphorylated 
NLGN4X T707 achieved by PMA activation normalized to no treatment (n = 4) and + 

















































































 We set out to examine whether other NLGN isoforms, like NLGN1, were 
regulated by phosphorylation. We identified a PKC phosphorylation site on human 
NLGN4X at T707, which establishes a novel interplay between two critical constituents 
of the synapse. It was to our surprise, R704, a residue mutated in a familial case of autism 
(Yan et al., 2005), resided within the PKC consensus sequence in the c-tail of NLGN4X. 
However, after identification, it was not unexpected that the autism mutation (R704C) 
abolished the kinase’s ability to chemicaly modify NLGN4X at T707. Using a diverse 
combination of techniques, we show that phosphorylated NLGN4X can dynamicaly 
enhance excitatory synapses. 
 Prior to this report, the importance of protein phosphorylation on NLGN1 was 
established (Bemben et al., 2014; Giannone et al., 2013). CaMKI phosphorylation of 
T739 regulates NLGN1’s ability to potentiate excitatory synaptic transmission by 
regulating its surface expression. This curent study demonstrates that PKC 
phosphorylation of T707 dramaticaly enhances NLGN4X’s ability to potentiate 
excitatory curents independent of modulating its surface expression. Therefore 
phosphorylation is a key regulatory modification modulating both NLGN1 and 
NLGN4X’s function but by diferent kinases, at diferent sites, and likely by diferent 
molecular mechanisms. Colectively, these studies raise two exciting questions: Might 
other kinases phosphorylate NLGN2 and NLGN3 and regulate their synaptic functions 
similarly to NLGN1 and NLGN4X? Secondly, what is the molecular mechanism by 
which T707 phosphorylation induces the genesis of functional synapses independent of 
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surface expression? These answers remain to be elucidated but are curently an area of 
future investigation. 
 Interestingly, human NLGN4X is not wel conserved in rodents, unlike NLGN1, 
NLGN2, and NLGN3. NLGN4 is absent in Ratus norvegicus and highly divergent and 
on an autosome in Mus musculus (Boliger et al., 2008). This has made the investigation 
of human autism mutations in NLGN4X chalenging and led some researchers to study 
the R704C point mutation in NLGN3. Although R704 is conserved in al human NLGNs, 
the residue analogous to NLGN4X T707 is not conserved. A knock-in mutation in 
NLGN3 resulted in minor synaptic phenotypes (Etherton et al., 2011). Therefore we 
believe it is imperative to study the R704C mutation in NLGN4X, and more generaly for 
al disease mutations to be studied in their respective isoforms independent of residue(s) 
conservation. 
 Canonicaly, NLGN1 is known as a critical component of the excitatory synapse 
based on its celular localization (Chih et al., 2005; Song et al., 1999), regulation by 
CaMKI (Bemben et al., 2014), and its ability to robustly potentiate AMPAR and 
NMDAR postsynaptic curents (Chubykin et al., 2007; Shipman et al., 2011). 
Conversely, mouse NLGN4 is known to localize to and modulate inhibitory transmission 
(Hoon et al., 2011). However, the human and mouse isoforms are not wel conserved. 
This raises the possibility that these proteins might perform distinct functions in diferent 
species. Here, we show that like NLGN1, human NLGN4X can enhance excitatory 
synapses, suggesting that NLGN4X may associate with excitatory synapses in humans. 
At a minimum, this underscores the reservations of studying human NLGN4X and rodent 
NLGN4 interchangeably. However, it is important to note our study does not preclude the 
	  
93	  
possibility that human NLGN4X may act or be expressed at inhibitory synapses in 
humans.  
 Notably, al the NLGN-associated autism point mutations reported thus far reside 
in their extracelular or transmembrane domains, except for NLGN4X R704C. This may 
be a result of chance or may highlight the critical importance of T707 phosphorylation in 
regulating NLGN4X’s synaptic properties. It is tempting to speculate whether this 
phosphorylation occurs at a critical developmental period to shape synaptic properties or 
whether it is a global switch that happens continualy at excitatory synapses. The 
profound efect the phospho-mimetic mutation (T707D) has on excitatory synapses may 
suggest the prior. 
 Mouse models of autism have increasingly revealed underlying imbalances of 
excitatory/inhibitory transmission, which are believed to play a central role in the 
etiology of ASDs (Foldy et al., 2013; Rothwel et al., 2014; Tabuchi et al., 2007). Our 
results are consistent with this hypothesis, which support a pathophysiological model by 
which NLGN4X R704C decreases excitatory transmission by abolishing PKC-mediated 
NLGN4X potentiation of excitatory transmission. Furthermore, we believe given the 
overlap of synaptic proteins found to be candidate genes in ASDs that by understanding 
the biology of specific mutations such as R704C has implications for clinical research, as 
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MATERIALS and METHODS 
Plasmids and Antibodies. Human pCAG-NLGN4X (WT, R704C, T707A, or T707D)-
IRES-mChery, pCAG-eGFP, pCAG-NLmiRs-GFP, and pRK5-FLAG-GluA1 plasmids 
were used for biochemical, electrophysiological, and imaging (synaptic markers) 
experiments. Human pCAG-HA-NLGN4X (WT, R704C, T707A, or T707D) were used 
in surface expression imaging experiments. pGEX-GST-NLGN c-tail constructs were 
made as previously described (Bemben et al., 2014). Point mutations were introduced 
using QuikChange Site-Directed mutagenesis. The primers used to construct NLGN4X 
R704C were Forward (FOR) 5’ - ACAAAAAGGACAAGAGGTGCCATGAGACTCA 
CAGG - 3’ and Reverse (REV) 5’ - CCTGTGAGTCTCATGGCACCTCTTGTCCTTTT 
TGT - 3’, NLGN4X T707A were FOR 5’ - AGGCGCCATGAGGCTCACAGGCGCC - 
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3’ and REV 5’ - GGCGCCTGTGAGCCTCATGGCGCCT - 3’, and NLGN4X T707D 
were FOR 5’- GAGGCGCCATGAGGATCACAGGCGCCCC - 3’ and REV 5’ - 
GGGGCGCCTGTGACCTCATGGCGCCTC - 3’. The primers used to insert the HA-tag 
in pCAG-NLGN4X were FOR 5’- TATCCATACGACGTTCCGGACTACGCTCCAGT 
TGTCAACACAAATTATGGC -3’ and REV 5’- AGCGTAGTCCGGAACGTCGTATG 
GATAATACTGTGCTTGGCTGTCAATGAG -3’. To generate the rabbit NLGN4X 
pT707-Ab (against residues 703-712 in NLGN4X), animals were immunized with 
synthetic phosphopeptide Ac-CKRRHE(pT)HRRP-amide (New England Peptide). Al 
Immunobloting with the NLGN4X T707-Ab began with blocking in 5% 
PhosphoBLOCKER (CELL BIOLABS, INC) at room temperature, folowed by 1% 
PhosphoBLOCKER in the primary and secondary Ab incubations. Antibodies used in the 
study were anti-NLGN4X (Sigma), anti-NLGN4X (abcam), anti-pan NLGN 4F9 
(Synaptic Systems), anti-GST (Bethyl Laboratories), anti-FLAG (Sigma), anti-HA rat 
(Roche), anti-HA rabbit (abcam), anti GluA1 pS831 (Covance), anti-PSD-95 
(Neuromab), anti-VGLUT1 (Milipore), anti-MAP2 (Cel Signaling), and anti-actin 
(ABM). Al antibodies were used at 1 µg/µL. 
GST-Fusion Protein Production, In Vitro Phosphorylation, and Mass Spectrometry. 
Reagents were prepared and assays were performed and analyzed as previous described 
(Bemben et al., 2014). 
Immunobloting. HEK293T cels were maintained, transfected, and proteins were 
isolated as previously described (Bemben et al., 2014). Treatment with 200 ng/µL PMA 
(Tocris) or DMSO (Sigma) began 30-60 minutes before protein isolation. For IPs, cel 
lysates were incubated with 6 µg of NLGN4X pT707-Ab and protein A-Sepharose beads 
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(GE Healthcare) at 4°C overnight. The folowing day the IPs were washed in TBS bufer 
containing 150 mM NaCl, 50 mM Tris-HCl, 1 mM EDTA, protease (Roche), and 
phosphatase (Sigma) inhibitors. The antibody conjugated beads were resuspended in 
SDS-PAGE sample bufer and subjected to Western bloting. 
Neuronal Cultures and Immunocytochemistry. Hippocampal neurons were prepared 
from E18 Sprague-Dawley rats and used for al immunocytochemistry experiments. The 
use and care of animals used in this study folowed the guidelines of the NIH Animal 
Research Advisory Commitee. Neurons were grown on precoated poly-D-Lysine 
(Sigma) glass coverslips and co-transfected (Liptofectamine 2000) at DIV10 with 
NLmiRs and HA-NLGN4X constructs for surface expression experiments and without 
the HA tag for staining with synaptic markers. Cels were fixed at DIV 14. Spine number 
was counted using the GFP signal from the NLmiRs construct from 3-4 regions of 30 
µm/cel. Methods, reagents, and analysis for imaging were done as previously described 
(Bemben et al., 2014). 
Electrophysiology. Hippocampal organotypic slice cultures were prepared from 6–8 day-
old rats as described previously (Stoppini et al., 1991). Al experiments were performed 
in accordance with established protocols approved by the University of California San 
Francisco Institutional Animal Care and Use Commitee. 
Sparse biolistic transfections of organotypic slice cultures were performed 4 days after 
culturing as previously described (Schnel et al., 2002). Briefly, 100 µg total of mixed 
plasmid DNA was coated on 1 µM-diameter gold particles in 0.5 mM spermidine, 
precipitated with 0.1 mM CaCl2, and washed four times in pure ethanol. The gold 
particles were coated onto PVC tubing, dried using ultra-pure N2 gas, and stored at 4°C in 
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desiccant. DNA-coated gold particles were delivered with a Helios Gene Gun 
(BioRad). When biolisticaly expressing two plasmids, gold particles were coated with 
equal amounts of each plasmid and plasmids always expressed diferent fluorescent 
markers. Observed frequency of coexpression was nearly 100%. Slices were maintained 
at 34 °C with media changes every other day. 
Recordings  were  performed at DIV  7-8 after  3-4  days  of expression.  Dual  whole-cel 
recordings in area  CA1  were  done  by simultaneously recording responses from a 
fluorescent transfected  neuron and  neighboring  untransfected control  neuron.  Synaptic 
responses were evoked by stimulating with a monopolar glass electrode filed with aCSF 
in stratum radiatum  of  CA1.  Typicaly each  pair  of  neurons is from a separate slice, 
whereas on rare occasions two pairs may come from one slice. For al paired recordings, 
the number of experiments (n) reported in the figure legends refer to the number of pairs. 
Pyramidal  neurons  were identified  by  morphology and location.  To ensure stable 
recording, membrane holding curent, input resistance, and pipete series resistance were 
monitored throughout recording. All recordings were made at 20-25°C using glass patch 
electrodes filed with an internal solution consisting of 135 mM CsMeSO4, 8 mM NaCl, 
10 mM HEPES, 0.3 mM EGTA, 4 mM Mg-ATP, 0.3 mM Na-GTP, 5 mM QX-314, and 
0.1 mM spermine and an external solution containing 119 mM NaCl, 2.5 mM KCl, 4 mM 
MgSO4, 4 mM CaCl2, 1 mM NaH2PO4, 26.2 mM NaHCO3 and 11 mM glucose bubbled 
continuously  with  95%  O2 and  5%  CO2.  Recordings  were  made in the  presence  of 
picrotoxin (100 µM) to block inhibitory curents and a smal (50 nM) amount of NBQX 
to reduce epileptiform activity at −70  mV (AMPA) and  +40  mV (NMDA).  AMPAR-
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mediated curents were measured at the peak of the curent, whereas NMDAR-mediated 
curents were measured 150 ms after the stimulation. 
Human Neuron Cultures. Human fetal neural cels were cultured as previously reported 
(Wang et al., 2006). Total NLGN4X protein was quantified using the anti-NLGN4X Ab 
(Sigma). 
Statistical Analysis. Statistical significance of immunoblots was tested using a t-test, 
immunocytochemistry with a one-way ANOVA, paired whole-cel recordings with a 
Wilcoxon signed-rank test, and comparisons between sets of paired data with a Mann-















 The folowing section contains supplemental figures describing additional data 
that was previous published (Bemben et al., 2015a) that supports our conclusions from 
the Results Section. The materials and methods for these experiments are explained in the 




























Supplementary Figure 4-1. Alignment of the Transmembrane Domains and 
Complete c-tails of Human NLGN1, NLGN2, NLGN3, NLGN4X, and NLGN4Y. 
The PKC phosphorylation site boxed in orange; key autism residue boxed in blue, and 
















Supplementary Figure 4-2. Autism-Associated Mutation does not Reduce CaMKII 
Phosphorylation of NLGN4X. A .Purified CaMKI and [γ-P-32]ATP were incubated 
with GST-fusion proteins and analyzed by autoradiography. CBB protein staining was 
used to visualize total protein, and GST (negative) and GST-NLGN1 c-tail (positive) 
functioned as phosphorylation controls. B. Means ± SEM of phosphorylated NLGN4X 
by CaMKI normalized to WT (n = 4) for NLGN4X R704C (P > 0.05, n = 4) and 












































































































Supplementary Figure 4-3. NLGN4X pT707-Ab Specificaly Immunoprecipitates 
Phosphorylated NLGN4X. GFP or NLGN4X were transfected in COS cels and treated 
with DMSO (-) or PMA (+) and immunoprecipitated with pT707-Ab. Immunoblots were 
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Supplementary Figure 4-4. NLmiRs Reduces AMPA and NMDA currents. A. 
AMPAR-mediated EPSC scater plot. Expression of NLmiRs (3-4 days) results in a 
reduction of AMPAR-mediated curents compared to control, untransfected cels (P = 
0.0078, n = 8). Open circles are individual pairs, filed (in red) are mean ± SEM. Black 
sample traces are control, green are transfected. Scale bar represents 15 pA and 10 ms. 
Bar graph of data is transfected amplitude (NLmiRs) normalized to neighboring, non-
transfected cel (control). B. NMDAR-mediated EPSC scater plot, showing similar 
reductions in NMDAR-mediated curents (P = 0.0098, n = 10) as seen in A. Scale bar 




































































































































Chapter	  5	  entitled	  Protein	  Kinase	  C-­Mediated	  Neuroligin-­3	  Ectodomain	  





Neuroligins (NLGNs) are cel adhesion molecules that form a transsynaptic interaction 
with neurexins that regulate synaptic function. NLGN3 is localized at excitatory and 
inhibitory synapses but the mechanisms underlying its traficking and elimination from 
the synapse remain unknown. Here, we report that protein kinase C (PKC) activation 
leads to the robust loss of NLGN3 protein. We show that this regulation is isoform- and 
kinase-specific and dependent on the NLGN3 extracelular domain. Therefore we report 
the first direct functional interplay between PKC signaling and NLGN3. Furthermore, we 
































	   NLGNs are postsynaptic cel adhesion molecules that are critical mediators of 
synapse development, maturation, and plasticity. NLGNs are one of the best-known 
inducers of synaptogenesis, underlying the critical importance of their regulation within 
the cel (Bemben et al., 2015b). Researchers have identified a mechanism that regulates 
how NLGN1 is traficked to the celular membrane, yet how NLGNs are removed from 
the synapse remains largely unknown (Bemben et al., 2014).  
 Synaptic activity induces local proteolytic cleavage and removal of NLGN1 from 
the synapse, which tunes down glutamatergic transmission (Peixoto et al., 2012; Suzuki 
et al., 2012). However, it stil remains a mystery if other NLGNs, which are expressed at 
diferent types of synapses, are subjected to the same type of regulation. 
 Moreover, an unbiased screen identified a NLGN3 protein product that acts as a 
mitogen to promote glioma growth. The protein product was identified by mass 
spectrometry (MS) in the celular media and contained only the extracelular domain 
(ECD) and not the intracelular domain (ICD) of NLGN3, suggesting it was a product of 
NLGN3 proteolytic cleavage. However, the MS coverage was incomplete of the ECD 
and ectodomain shedding of NLGN3 has not been empiricaly shown. Criticaly, this 
provides a potential link between synapse regulation and brain cancer (Venkatesh et al., 
2015). 
 These studies ofer a possible explanation for how NLGN3 may be removed from 
the synapse, similarly to NLGN1, but does not provide evidence for the functional 
consequences of removal from the synapse. Interestingly, it also implies that that ECDs 
and ICDs may not simply be degraded after proteolytic cleavage but may provide 
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auxiliary functions such as the NLGN3 ECD promoting glioma growth. Might the 
NLGN3 ECD have a physiological role in the nervous system? 
 Here, we show that PKC activation leads to the rapid loss of celular NLGN3, 
which is dependent on its ECD. This establishes that NLGN3 protein can undergo 
ectodomain shedding. Moreover, it identifies an isoform specific pathway that can 






































PKC Activation Induces Loss of NLGN3 Protein 
 Previously, we have shown that PKC phosphorylation of NLGN4X induces 
excitatory synaptogenesis. Interestingly, NLGN4X was the only neuroligin isoform to be 
robustly phosphorylated by PKC (Bemben et al., 2015a). Although not directly 
phosphorylated by PKC, we uncovered that PKC activation leads to the removal of total 
NLGN3 protein from celular lysate and subsequent accumulation in the celular media 
(Figure 5-1A-C). NLGN1, NLGN2, and NLGN4X did not show similar reductions in 
protein levels or accumulation of the ECD in the media. Moreover, cAMP-dependent 
protein kinase (PKA) signaling did not result in a decrease of NLGN3 protein levels 
(Figure 5-2A-C). Intriguingly, NLGN1 and NLGN3 were identified in the media, 
suggestive of a basal mechanism of protein turnover for these isoforms. Taken together, 
these results indicate an isoform- and kinase-specific signaling pathway regulating 
NLGN3 protein levels.  
 To test if NLGN3 ectodomain shedding was dependent on its extracelular (ECD) 
or intracelular domain (ICD), we engineered chimeras NLGN1 ECD / NLGN3 ICD 
(NLGN1/3) and NLGN3 ECD / NLGN1 ICD (NLGN3/1) and found NLGN3 protein loss 
was dependent on the NLGN3 ECD (Figure 5-3A-C). This indicates that NLGN3 
ectodomain shedding is not dependent on PKC phosphorylation of the intracelular 











Figure 5-1. PKC-Mediated NLGN3 Protein Loss in Heterologous Cels. A. Schematic 
of neuroligin subtypes. B. Total neuroligin levels in cels (lysate) and in culture media 
(media) in HEK293T cels under control conditions (DMSO) or in the presence of 
phorbol 12-myristate 13-acetate (PMA), a transient activator of PKC. Immunoblots were 







































































































or NLGN4 normalized to actin control (n = 5) with NLGN1 + PMA (P > 0.05), NLGN2 
































Figure 5-2. PKA does not Induce Neuroligin Protein Loss. A. Total neuroligin levels 
in cels (lysate) and in culture media (media) in HEK293T cels under control conditions 
(DMSO) or in the presence of forskolin (FSK), a transient activator of PKA. 
Immunoblots were probed with indicated antibodies. NLGN2 phosphorylation served as 
a positive control for FOR treatment. B. Means ± SEM of total NLGN1, NLGN2, 
NLGN3, or NLGN4 normalized to actin control (n = 3) with NLGN1 + FSK (P > 0.05), 










































































































































Means ± SEM of phosphorylated to total NLGN2 normalized to DMSO control (n = 3) 












Figure 5-3. PKC-mediated NLGN3 Protein Loss is Dependent on its Extracelular 
Domain. A. Schematic of neuroligin subtypes. B. Total neuroligin levels in cels (lysate) 
and in culture media (media) in HEK293T cels under control conditions (DMSO) or in 
the presence of phorbol 12-myristate 13-acetate (PMA), a transient activator of PKC. 
Immunoblots were probed with indicated antibodies. C. Means ± SEM of total NLGN1, 














































































































PMA (P > 0.05), NLGN3 + PMA (P = 0.0009), NLGN1/3 + PMA (P > 0.05), or 





































 The importance of the NLGN3 ECD remains unquestioned. The NLGN3 ECD 
promotes glioma growth and its expression inversely corelates with survival in human 
glioblastoma (Venkatesh et al., 2015). Identification of the protease(s) that cleaves 
NLGN3, how it is regulated, and the receptor that NLGN3 ECD binds to in glioma cels 
to promote proliferation may lead to cancer therapeutics and underlies our biochemical 
goals for this project. 
 Secondly, when proteins are cleaved by proteases, they are most often 
subsequently degraded, removed, and no longer provide a function within or at a nearby 
cel. However, the fact that the NLGN3 ECD can induce proliferation in glioma cels 
provides an alternative explanation that the NLGN3 ECD may provide a function after 
proteolytic cleavage (Venkatesh et al., 2015). The initial finding focused on the NLGN3 
ECD function in cancer cels but suggests that maybe the NLGN3 ECD or ICD may 
serve a role within the nervous system, an area of curent focus. 
 It is dificult to predict the direction of a project in its infancies. However, if we 
find the NLGN3 ECD to have a function within the nervous system, we wil look at the 
other NLGN isoforms to see if they may have a similar or disparate function. Moreover, 
it is clear that NLGN1 and NLGN3, the two NLGN isoforms localized at excitatory 
synapses, undergo proteolytic cleavage. Is this solely a mechanism to regulate excitatory 
synapses or do inhibitory NLGN isoforms, such as NLGN2, undergo a similar process? 
Regardless of the answers to these questions, the NLGN3 ECD remains an exciting area 
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MATERIALS and METHODS 
Immunobloting. HEK293T cels were maintained, transfected, and proteins were 
isolated as previously described (Bemben et al., 2014). Treatment with 200 ng/µL PMA 
























































 The discovery of neuroligins twenty years ago unlocked new avenues of research 
into the molecular dynamics of the synaptic site. The research that has folowed has 
greatly enhanced our understanding of functional synaptogenesis in the developing and 
mature brain. The involvement of neuroligins in cognitive disorders and more recently 
cancer underlies the broad interest and critical importance of their investigation. These 
preliminary investigations have enabled researchers to develop genetic models to study 
the etiology of these diseases and one day wil hopefuly lead to therapeutics (Bemben et 
al., 2015b). 
 The preliminary studies on neuroligins focused on two key aspects: 1) their ability 
to induce synaptogenesis, and 2) their ability to eliminate synapses when reduced from an 
individual cel. These now canonical studies have made neuroligins the gold standard of 
molecules that dynamicaly form and modulate synapses. Since their initial identification, 
neuroligins have garnered broad interest from the scientific community, but many key 
questions stil remain unanswered. For example, if neuroligins are such key mediators of 
synaptic function, how does the cel transiently regulate or faithfuly modify these 
molecules to prevent aberant expression, which would be detrimental to the cel? 
Secondly, how does a single molecule recruit the machinery necessary to form a 
functional synapse? 
 My dissertation research atempted to answer these questions and expand on the 
limited research on the regulation of neuroligin proteins. We reasoned that neurons need 
to tightly regulate potent synaptic inducers, such as neuroligins, as loss of control would 
lead to too many or too few synapses on a particular neuron. In Chapter 3, we identified 
an individual phosphorylation site on neuroligin-1 that drasticaly efects its expression 
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on the plasma membrane. If neuroligin-1 is unable to achieve surface expression, it 
cannot induce synaptogenesis, essentialy rendering the protein inactive. In short, this 
postranslational modification acts as an on/of switch for neuroligin-1 function, which 
argues against dogma that neuroligins are only static building blocks of a synapse and 
cannot be transiently activated molecules. Although this chapter focused on a single 
neuroligin isoform, it is reasonable to hypothesize that other neuroligin isoforms may be 
modified in a similar fashion and is under curent investigation in the Roche Laboratory. 
Furthermore, it begs the question if other postranslational modifications regulate 
neuroligin proteins? Researchers have taken a holistic approach at comparing neuroligin 
isoforms and found they are highly conserved. However, diferent neuroligin isoforms 
are able to induce diferent types of synapses, which requires recruiting vastly diferent 
celular machinery. Which domains within neuroligins are critical for this isoform 
specificity remains an enigma, but our research sheds light on the need to dissect these 
molecules on what may be single amino acid diferences, such as a phosphorylation site, 
to elucidate critical isoform-specific domains. 
 This approach led us to another key finding in the neuroligin field, which focused 
on how an individual molecule can recruit the necessary machinery and generate a 
functional synapse. In Chapter 4, we uncovered a phosphorylation site on neuroligin-4X 
that enables this isoform to robustly generate excitatory synapses. In contrast to 
phosphorylation of the cytoplasmic tail (c-tail) of neuroligin-1 regulating surface 
expression and thereby its ability to generate synapses (Chapter 3), phosphorylation of 
neuroligin-4X c-tail did not regulate its expression on the plasma membrane but led to the 
robust genesis of functional excitatory synapses. Hence, the title of the thesis, A Tale of 
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Two C-Tails, describing how phosphorylation on a diferent site in neuroligin-1 and 
neuroligin-4x can lead to the genesis of excitatory synapses but by independent 
mechanisms. Then how might neurolgin-4X phosphorylation induce the genesis of 
synapses independent of regulating surface expression? 
 Unfortunately, we have not uncovered this mechanism of synaptic enhancement 
but it is under curent investigation. We reason this could be achieved in several ways. 
The most likely of these hypotheses is that phosphorylated neuroligin-4X binds to a 
linker or scafolding protein that promotes the recruitment of excitatory synapse 
machinery such as glutamate receptors. To the best of our knowledge, there are few 
published reports of proteins that bind to neuroligin-4X, therefore we do not have many 
candidate molecules to test. An unbiased screen for diferential binding partners of 
non/phosphorylated neuroligin-4X protein could potentialy yield interesting results. A 
second hypothesis is that phosphorylated neuroligin-4X could increase the binding 
afinity for neurexin, which would result in an increase in synaptogenesis. We deem this 
scenario to be less likely because it would require an intracelular modification 
(phosphorylation) to result in a conformational change in the extracelular domain 
(location of neurexin binding site) on neuroligin-4X. Regardless of the mechanism, 
elucidating this pathway wil deepen our understanding of synaptogenesis in the brain. 
For detailed analysis on neuroligin-1 and neuroligin-4X phosphorylation, please refer to 
those individual sections. 
 Phosphorylation of neuroligin-1 and neuroligin-4X focused on how neuroligins 
are traficked to synaptic sites and promote synaptogenesis. However, how are 
neuroligins removed from the synapse and what are the functional consequences of this 
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release from the synaptic site? While we were studying protein kinase C phosphorylation 
of neuroligin-4X, we observed an unusual phenomenon. Whenever we activated protein 
kinase C within the cel, nearly al neuroligin-3 protein was degraded and the 
extracelular domain was released into the media. Although interesting, this result piqued 
our interest when an unbiased screen found the extracelular domain of neuroligin-3 
could act as a mitogen to promote glioma growth (Venkatesh et al., 2015). The 
neuroligin-3 ectodomain acts as a ligand on glioma cels to change gene expression, 
establishing a new or of-target function for neuroligins. The importance of the 
neuroligin-3 ectodomain was identified in this study, but it did not provide any 
information on the production of the truncated form of neuroligin-3. Moreover, given the 
fact that the neuroligin-3 ectodomain provides a function outside the nervous system, 
might it also provide one in the nervous system? For example, could it act as a dominant 
negative by binding to neurexins without its c-tail, and therefore be unable to recruit 
synaptic receptors, thus suppressing synaptic transmission? 
 These are questions we wil be investigating in the future. However, uncovering 
the mechanism of proteolytic processing to produce the neuroligin-3 ectodomain wil be 
useful in cancer therapeutics. For example, the protease that cleaves neurolgin-3 in 
neurons or the receptor that binds the neuroligin-3 ectodomain in glioma cels to promote 
cel proliferation are potential drug targets. 
 Despite outstanding advances in the field, many key questions remain unsolved. 
Furthermore, as investigations continue on neuroligins, new functions continue to be 
identified. Our results described in this thesis expand our knowledge and identify new 
mechanisms of acute activation of neuroligin proteins. This shift in focus from 
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neuroligins as static to transient synaptic molecules may change the direction of future 
research in the field. The scope of diseases with which neuroligins are associated 
continues to expand and now range from autism spectrum disorders to cancers. This 
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section, immunohistochemistry, In situ hybridization on tissue sections, RNA isolation 
and production of cDNA RT-PCR, Real time PCR, Western blots, designing and 
purifying antibodies, immunoprecipitations, producing and isolating proteins in bacteria, 
in vitro phosphorylation assays, isolation of primary neuronal cultures, versed in using 
and accessing genome databases (Ensembl & BioGPS), Lasergene, MetaMorph, MFold, 
Microsoft Ofice, Prism, Adobe Software, and basic molecular biology lab techniques 





 Johns Hopkins University: 
 
Teaching Assistant for Developmental Biology 373                      01/11-5/11 
Contact: Dr. Carolyn Noris (410) 516-7330             E-mail: crn@jhu.edu  
Address: 308 Mudd Hal 
        3400 North Charles Street 
        Baltimore, MD 21218-2685 
 
Taught and lectured junior and senior undergraduates in an upper level biology course 
Teaching Assistant for Biochemistry 306                             09/10-12/10 
Contact: Dr. Robert Horner (410) 516-8067              E-mail: rdhorner@jhu.edu 
Address: 313 Macaulay Hal 
        3400 North Charles Street 
        Baltimore, MD 21218-2685 
 



















 Graduate School Newspaper                                      07/10-08/13 
Writer and Co-editor 
 
Began as a writer and advanced to a Co-editor for the GSChronicles, a monthly 
publication highlighting graduate student activities and science articles of interest at the 
National Institutes of Health. Provided an opportunity to further advance my writing skils 
and work on a team to produce an electronic newspaper. 
 
Graduate Student Writer/Editor                                  04/11-07/11 
Writer & Editor, Ofice of Pre-Professional Programs, Johns Hopkins University 
Contact: Ana Droscoski (410) 516-4140 
Address: Garland Hal Suite 300                        E-mail: adrosco1@jhu.edu 
         3400 North Charles Street                       
         Baltimore, MD 21219 
 
Wrote and edited student cover leters that were submited to graduate universities 
(medical school, law school, and various PhD programs) with the students’ application on 
behalf of Johns Hopkins University. These cover leters were composed of summaries of 
the students’ research experience, academic performance, volunteer activities, as wel as 




 Society for Neuroscience                                        05/09-Present 
Curent member and presenter at the annual Society for Neuroscience Conference in 2009 
(Chicago, IL), 2013 (San Diego, CA), and 2015 (Chicago, IL). 
 
Footbal Referee/Coach (Montgomery County, MD)                   08/13-12/13 
Instructor, coach, and referee for youth footbal games in Kidbal Organization.             
Contact Information: Ronnie Jenkins (301) 983-0543 
 
Big Brothers Big Sisters of America (Washtenaw County ofice, MI)     01/09-05/10 
Big brother (mentor) for a 12- year old boy. Activities included community service, 
educational activities, and developmental programs. 
 138 
Contact Information: Melanie Shaw (734) 975-4086 EXT. 110 
 
Phi Kappa Psi Fraternity (Michigan Alpha Chapter)                   01/06-05/09 
Vice president of pledge class and participated in philanthropic events (Relay for Life and 
Secret Santa). 
 
 
 
